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 Cancer patients treated with adjuvant chemotherapy often experience cognitive 
decline following treatment.  This phenomenon, often dubbed ―chemo brain‖ or ―chemo 
fog‖ is usually temporary, but for a subset of survivors, these cognitive impairments can 
be long-lasting (>10 years) and negatively affect patients‘ quality of life, career 
performance, and social fulfillment.  While it is unclear what neurobiological 
mechanisms underlie chemotherapy related cognitive impairment, the majority of the 
animal literature has focused on adult neurogenesis.  One process important for 
neurogenesis is the proliferation of new neurons within the dentate gyrus of the 
hippocampus.  It is evident that many chemotherapy agents can negatively impact levels 
of neurogenesis shortly after treatment.  However, only a few studies have investigated 
the long-term impact of chemotherapy on neurogenesis.  The present studies explore the 
long-term impact of three commonly used chemotherapy agents on neurogenesis utilizing 
immunohistochemistry in a male C57BL/6J mouse model. EXP 1:  The effects of 
cyclophosphamide or doxorubicin on neuronal proliferation were evaluated at 1 day, 56 
  
days and 6 months post-treatment.  Results indicated that neither cyclophosphamide nor 
doxorubicin treatment altered proliferation rates across either short-term or long-term 
intervals.  EXP 2:  The effects of 5-FU (alone or in combination with either the 
antioxidant melatonin or the antidepressant fluoxetine) on neuronal proliferation were 
evaluated at 1 day, 56 days and 6 months post-treatment.  The results indicated that there 
was no effect of 5-FU or neuroprotectant treatment at any time point. The current studies 
suggest that neither cyclophosphamide, doxorubicin, nor 5-FU affect neurogenic 
proliferation in C57BL/6J mice directly after injection or up to 6 months post injection.  
As such, impaired neurogenic proliferation is an unlikely cellular mechanism for 
chemotherapy related cognitive impairment detected within this strain. 
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INTRODUCTION 
The American Cancer Society estimates 1.7 million new patients will be 
diagnosed with cancer in the US in 2017.  Fortunately, advancements in early detection 
and treatments have led to steadily increasing 5 year survival rates from 48.7% in 1975 to 
68.5% in 2006 (National Cancer Institute, based on data from SEER 9 Incidence & U.S. 
Mortality 1975-2013).  Survival rates are particularly high for some cancers.  For 
example, the 5 year survival rate for breast cancer increased from 75.2% in 1975 to 
90.6% in 2008.  As the number of surviving patients dramatically increases, research 
regarding the long-term side effects of different cancer treatment strategies has become 
progressively more important;  patients who would not have survived their cancer in 
previous generations now present their treatment specialists and doctors with a new set of 
problems as the long-term side effects of cancer treatments become evident.  One major 
source of these long-term side effects is treatment with chemotherapy compounds. 
Cognitive impairment is one of the most commonly reported long-term side 
effects of chemotherapeutic treatment (Boykoff et al., 2009).  Complaints regarding 
problems in mental function are referred to as chemotherapy related cognitive 
impairment (CRCI) in the literature, but are also often dubbed chemo-brain or chemo-fog 
(Farrell at al., 2013).  Research conducted in humans regarding CRCI focuses primarily 
on those reported in breast cancer patients.  These patients generally have a better 
prognoses and higher rates of survival that allow for easier recruitment and long-term 
cognitive assessment when compared to patients with other types of cancer.  As a result, 
many of the first reported complaints of cognitive decline following chemotherapy 
treatment were detected in breast cancer patients. 
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Cognitive problems detected in breast cancer patients varies from study to study, 
but the most common complaints seem to be associated with decreased memory, 
difficulty focusing, and trouble multitasking.  These cognitive problems are typically 
reported as mild to moderate when compared to relative normative ranges or healthy 
controls in neuropsychological evaluation (Ahles & Saykin, 2001; Staat & Segatore 
2005).   A meta-analysis conducted by Vardy et al. (2007) examined the evaluation of 
cognitive function associated with chemotherapy related impairment.  Deficits were 
reported across a diverse range of processes, including: working memory, attention, 
processing speed, concentration, and executive functions.  Cognitive problems were 
noted to occur intermittently, making it difficult to obtain objective measures of cognitive 
impairment using traditional neuropsychological assessment (Vardy et al., 2007).  While 
severity of impairments are often categorized as mild to moderate, Staat and Segatore 
(2005) suggest that clinical presentation of CRCI can include increased levels of stress, 
serious detriments in the ability of patients to multitask, and poorer performance when 
both acquiring new skills and returning to environments with high-level cognitive 
demands.  Furthermore, Olin (2001) concluded that once patients successfully survive the 
diagnosis and treatment of cancer, the realization of ongoing mild cognitive impairment 
and inability to return to pre-treatment levels of functioning can be devastating.  Even 
mild impairments may lead to a diminished quality of life when capacity to carry out 
daily activities or future occupational and educational potential is adversely impacted. 
Human Literature 
In 1980, Peter Silberfarb and colleagues investigated the cognitive outcomes of 
patients given various chemotherapy treatments.  This study is one of the earliest to 
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recognize reduced scores on standard neuropsychological tests in patients that received 
chemotherapy that had not been directed at the central nervous system (CNS).  Silberfarb 
et al. (1980) reported that systemic chemotherapy treatment was significantly associated 
with poor cognitive test scores, regardless of the primary site of the cancer and whether 
or not there was metastasis to the brain.  Prior to this discovery, many of the complaints 
of cognitive decline following chemotherapy treatment were dismissed by the medical 
community as psychological rather than neurological.  It was thought that many of the 
agents used to treat cancer could not penetrate the blood-brain barrier (BBB) and thus 
were unlikely to cause neurotoxicity when administered systemically (Raffa & Tallarida, 
2010).  With Silberfarb et al.‘s (1980) findings, interest in the cognitive impairment seen 
following chemotherapy has increased exponentially (Raffa & Tallarida, 2010).   
Prevalence and Assessment Variables 
Reported rates of CRCI in patient populations vary drastically from study to 
study.  Some studies report rates as low as 17% (Schagen et al., 2001) while others have 
reported rates up to 95% (Komaki et al., 1995).  Most researcher agree that only a subset 
of patients treated with chemotherapy develop long-lasting (>10 years) cognitive 
impairment that can severely impact quality of life (Ahles & Saykin 2001; Raffa & 
Tallarida, 2010).   There is an important distinction between cognitive impairments 
detected during or shortly after chemotherapy treatment and those impairments that are 
maintained or return long after treatment cessation.  Although it is quite common for 
patients treated with chemotherapy to experience cognitive problems immediately 
following treatment, for many, these problems subside after recovery (Ahles & Saykin, 
2001; Ferguson & Ahles 2003).  Discrepancies in the prevalence of CRCI within the 
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literature are at least in part due to conflating those patients experiencing only short-term 
CRCI with those that develop long-lasting impairments.  In addition, a variety of 
experimental design factors may also contribute to variability across study results.  These 
factors include: timing of the assessment, type of assessment (e.g. self-report, 
neuropsychological testing, brain imaging), and the comparison group chosen (e.g. 
healthy controls, normative ranges, use of matched non-chemotherapy controls, pre-
chemotherapy baseline) (Castellon et al., 2005; Vardy et al., 2007; Farrell at al., 2013; 
Evenden, 2013). 
Type of Assessment:  A variety of assessment methodologies have been used within the 
CRCI research literature.  Typically the highest rates of impairment are generated from 
subjective self-reports.  In 2006, Hurria and colleagues found that over half (51%) of 
their sample of 45 patients completing the Squire Memory Self-Rating Questionnaire 
before treatment and 6 months post-treatment perceived a decline in memory function 
post-chemotherapy.  In particular, patients reported a worsening of the ability to learn 
new information suggesting hippocampal involvement.  Although many patients exposed 
to chemotherapy treatment complain of cognitive problems in self-reported 
questionnaires, these subjective impairments are often not associated with actual 
problematic performance on neuropsychological evaluations in studies that have been 
conducted using both measures (van Dam et al., 1998; Castellon et al., 2004, 2005).  A 
review by Hutchinson et al. (2012) showed that relationships between objective and 
subjective measures of impairment reach significance in only 8 out of 24 studies 
examined.  Furthermore, of the 8 studies in which a relationship was found, most of the 
correlations were restricted to memory tests rather than overall or index scores on 
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neuropsychological batteries.  The questionable accuracy of subjective self-reports has 
driven more recent efforts within the research field to favor more formal, objective 
neuropsychological testing which typically indicate lower rates of CRCI.  Typical 
neuropsychological testing within the literature include multiple cognitive domains, but 
deficits are most often detected in tests of the following: verbal memory (e.g. Wechsler 
Memory Scale – Logical Memory, Memory Scanning Test, Hopkins Verbal Learning 
Test, Rey Auditory Verbal Learning Test), visual memory (e.g. Wechsler Memory Scale 
– Visual reproduction, Wechsler Memory Scale – Non-Verbal Memory,  Rey Osterreith 
Complex Figure), visuospatial function (e.g. Wechsler Adult Intelligence Scale – Block 
Design, Rey Complex figure – Copy Trial, Road Map Sense Test), processing speed (e.g. 
Wechsler Adult Intelligence Scale – Digit symbol, Monroe Sherman Reading 
Comprehension, Zazzo‘s Attention Test– Speed), and attention  (e.g. Paced Auditory 
Serial Addition Test, Stroop Test, Trail Making, Automated performance test system –
Sternberg Test, Simple Reaction Time) [as reported in Anderson-Hanley et al., 2003; 
O'Shaughnessy, 2003; Castellon et al., 2004, 2005; and Vardy et al., 2007].  
Timing of Assessment:  The timing of cognitive assessment relative to completion of 
chemotherapy treatment is critically important in determining the extent of CRCI.  Early 
studies such as those conducted by Komaki et al. (1995) or Wieneke and Dienst (1995) 
reported that 75 – 95% of their sample exhibited cognitive impairment shortly following 
treatment.  These high rates of CRCI are common in studies that assess patients within a 
time period of less than 6 months after cancer treatment.  According to Janelsins and 
colleagues (2014), up to 75% of patients report some form of chemotherapy related 
cognitive impairment during treatment.  However, only 35% of these patients experience 
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cognitive impairments that last for more than a few months.  Ferguson and Ahles (2003) 
suggested that one reason for the high level of impairment during or shortly after 
chemotherapy is that elevated levels of stress and fatigue may make neuropsychological 
assessment more difficult and contribute to an inflation of poorer performance on 
standardized measures, especially when comparing data to normative scores in the 
general population.  These factors most likely contributed to the high rates of detected 
impairment in Komaki et al. (1995) and Wieneke and Dienst (1995).   
     Assessment intervals that extend past 6 months commonly report much lower rates of 
CRCI (Schagen et al., 1999; Schagen et al., 2001; Ahles et al., 2002).  For instance, when 
neuropsychological assessments were conducted 2 years after treatment, Schagen et al. 
(2001) found only 17% of patients exhibited signs of CRCI.  van Dam et al. (1998) found 
similar results.  In their study, 32% of patients treated with high dose chemotherapy 
exhibited CRCI, while 17% of the standard dose group showed signs of CRCI 2 years 
after treatment.  In another study, Wefel et al. (2004) conducted comprehensive 
neuropsychological evaluation in a sample of breast cancer patients before treatment, at 6 
months after treatment, and 1 year after treatment.  The results indicated that while 61% 
of patients exhibited cognitive decline 6 months post-chemotherapy, only 30% of the 
total sample still exhibited impairment 1 year post-treatment. 
Taken together, these studies suggest that assessment of patients relatively soon 
after chemotherapy treatment may inflate rates of cognitive impairment if one is 
interested in understanding how many patients develop long-lasting CRCI; patients 
experiencing short-term CRCI and those that end up with long-lasting and potentially 
permanent CRCI are conflated in studies that use shorter assessment intervals.  Questions 
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raised by these early studies became the impetus for more rigorous longitudinal studies 
that favor designs with multiple time points over those that only assess cognitive function 
immediately following treatment. 
Control and Comparison Groups:  Another factor important for the classification and 
detection of CRCI within the human literature is the selection of a control or comparator 
population.  Given its medical efficacy in the treatment of cancer, ethical limitations 
within the human literature make it difficult for researchers to obtain comparator groups 
that are identical to the treatment group aside from chemotherapy.  Given that most of the 
CRCI research has been conducted in breast cancer patients and most women with breast 
cancer who participate in CRCI studies are often highly educated, it has been argued by 
Vardy et al. (2007) that test scores from this population may appear normal when 
compared to standard population scores even when these scores may represent a 
significant loss of function.  The selection of an appropriate comparator is thus an 
important factor within the CRCI literature and may play a role in the rates and degrees 
of impairment detected between studies. 
One common method that many studies have utilized to evaluate the cognitive 
outcomes of patients treated with chemotherapy has been to compare patients receiving 
only local cancer treatments (e.g. surgery or regional radiation therapy) with those 
patients receiving systemic chemotherapy.  Studies that compare rates of cognitive 
impairment between local therapy controls rather than healthy controls generally report 
lower rates of CRCI.  For example, in 2002 Ahles and collogues compared scores 
obtained from chemotherapy patients to a control group receiving local treatment rather 
than to normative population scores on neuropsychological tests, as in earlier studies.  
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The samples consisted of 35 chemotherapy and 36 local therapy long-term survivors 
(minimum of 5 years after diagnosis) with an average post-treatment assessment time 
interval of 10 years.  Testing consisted of a neuropsychological battery containing nine 
testing domains and several psychological tests including a test of depression, fatigue and 
anxiety.  Results indicated that patients treated with chemotherapy scored significantly 
lower than those that received local treatment on tests of verbal memory, psychomotor 
function, spatial ability and visual memory, even when controlling for age and education.  
Furthermore, 39% of chemotherapy patients compared with 14% of the local therapy 
patients were categorized as overall ‗low performing‘ on neuropsychological tests 
(defined as the lower quartile on the neuropsychological performance index).  
Chemotherapy treated patients also self-reported greater problems with working memory 
utilizing the Squire Memory Self-Rating questionnaire.  Similar results have also been 
obtained by Schagen et al. (1999) when comparing groups of cancer survivors that 
received chemotherapy or local treatment only, with assessments done approximately 2 
years after completing treatment.  Neuropsychological testing in the study revealed that 
28% of the chemotherapy group compared to 12% of the local therapy group scored two 
standard deviations below the mean of the local therapy control.  Consistent with 
previously discussed problems associated with self-report data, while interviews 
indicated that patients treated with chemotherapy complained of more concentration and 
memory related problems, no significant correlation was found between reported 
complaints and composite scores for either global or domain specific neuropsychological 
tests.  Similar results were obtained by Schagen et al. (2001), in which cognitive scores 
were compared across three groups: high dose chemotherapy, standard dose 
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chemotherapy and local therapy only.  Results indicated that 2 years after treatment, 
chemotherapy treated patients scored worse: 32% of the high-dose group, 17% of the 
standard-dose group and 9% of the local therapy group scoring under two standard 
deviations below the mean of the control group in neuropsychological examinations.  
These studies suggest that when cognitive scores are compared to a local therapy groups, 
a subset of individuals rather than the majority of those treated with chemotherapy show 
long-term impairment.    
The studies discussed so far highlight three major factors that seem to impact the 
detected rates of CRCI in any given sample.  These factors are: 1) type of assessment 
used, 2) timing of assessment relative to completion of treatment, and 3) the particular 
type of comparison group selected.  Regardless of the discrepancies present in the 
literature, there seems to be a general agreement that rates of CRCI should reflect long-
term cognitive dysfunction, such as the rates found in studies that examine patients at 
time points greater than 6 months after completion of treatment.  In addition, there is a 
growing consensus that the use of established neuropsychological batteries for the 
primary assessment of CRCI provides the clearest indicators of declining function.  
Studies that meet these criteria typically report that 17-34% of assessed patients 
demonstrate clear cognitive impairment following chemotherapy treatment. (Ferguson & 
Ahles 2003; Ahles & Saykin, 2007; McDonald, Saykin & Ahles, 2008).  Thus, only a 
subgroup of patients treated with chemotherapy suffer cognitive impairments that persist 
for at least a year after completion of treatment.   
While research efforts exploring the cognitive effects of chemotherapy have 
increased since the late 1990s, it can be argued that limited progress has been made 
 10 
elucidating the exact longitudinal aspects of CRCI, the extent to which various 
chemotherapy compounds differ in their capacity to induce CRCI, and in the 
identification of vulnerable brain structures and cellular mechanisms that underlie CRCI.  
Human studies are often limited to cross sectional experimental designs, have limited 
longitudinal access to patients, and have no control over the individualized and often 
complicated medical regimens of patients that include a large array of pharmaceutical 
compounds and therapy techniques.  These factors exemplify just a handful of confounds 
and methodological challenges that have been blamed for the slow progress within the 
field (Castellon et al., 2005; Vardy et al., 2007; Farrell at al., 2013; Evenden, 2013).  
Experimental challenges are further potentiated when comparisons are made across 
studies with different experimental designs, making data difficult to combine or compare 
results within the field.  As a result, many of the more recent achievements in the field 
have been in the development of new tools, experimental designs, and evaluation 
standards with which to overcome many of the confounding factors that have stifled 
progress.  In 2006, many of the key researchers in the field formed the International 
Cognition and Cancer Task Force (ICCTF) in order to establish guidelines for 
streamlining study methodologies to increase comparability across studies and to 
minimize the effect of confounds within the field in general (Vardy et al., 2008; Wefel et 
al., 2011).  As a result of the ICCTF‘s efforts, more recent work has centered on research 
approaches that examine patients longitudinally with longer post-treatment time intervals, 
that make comparisons with multiple control groups (healthy controls, local therapy, 
baseline measurements, and normative data) with agreed upon core neuropsychological 
tests of learning and memory, processing speed, and executive function [Hopkins Verbal 
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Learning Test-Revised, Trail Making Test, and the Controlled Oral Word Association 
(COWA) of the Multilingual Aphasia Examination] (Wefel et al., 2011).   
Neuroimaging: Initial Insult, Possible Recovery, and Permanent Decline 
Many recent attempts within the human literature to explore CRCI have also 
focused on combining new more powerful neuroimaging techniques like structural 
magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI) and 
diffusion tensor imaging (DTI) with performance on neuropsychological batteries and 
cognitive tests recommended by ICCTF.   
Structural Imaging: In 2010, McDonald and colleagues conducted one of the first 
longitudinal imaging studies to evaluate structural alterations in patients‘ gray matter 
density shortly after receiving chemotherapy and throughout the course of recovery.  
MRI imaging utilized voxel-based morphometry to measure gray matter density 
differences among groups (chemotherapy treated patients, non-chemotherapy patients, 
and healthy controls).  Participants were assessed before treatment, one month, and one 
year after treatment.  Results indicated that chemotherapy treated patients exhibited 
decreased gray matter density in parts of bilateral frontal, temporal, and cerebellar 
regions relative to baseline measurements when assessed one month after treatment.  
Data collected one year after treatment indicated that recovery had occurred in some of 
these regions, including superior areas of both frontal and temporal regions, but decreases 
were still detected in cerebellar regions and those more medial areas of both frontal and 
temporal regions suggesting that long-term structural changes took place.  This unique 
pattern of gray matter alteration was only found in the chemotherapy treated group.  
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Although McDonald et al. (2010) did not run a neuropsychological battery, they argue 
that the structural changes detected were consistent with the types of cognitive 
dysfunction and the pattern of complaints observed in previous studies of chemotherapy 
patients examined along the same time intervals.  Structural changes in the brain 
observed by McDonald et al. (2010) and cognitive deficits detected in other studies find 
the most pronounced deficits during and shortly after chemotherapy treatment.  These 
cognitive and structural effects abate for some during a recovery period in the following 
months to a year, with a subset of patients reporting persistent long-term cognitive 
problems that are consistent with alterations in gray matter density detected a year after 
chemotherapy treatment.  This study produced the first results indicating structural 
changes in the brain following chemotherapy treatment that were consistent with 
previous behavioral data, suggesting that structural changes in the brain may be related to 
reported cognitive problems.     
More recent studies utilizing MRI techniques to investigate structural changes 
include a cohort study conducted by Koppelman et al. (2012) in which total brain volume 
and gray matter volume were measured in a sample of 184 cancer survivors with an 
average of 21 years post-treatment.  Data collected from this sample was compared to an 
aged-matched cancer-free reference pool consisting of 368 subjects.  Comparisons 
indicated that chemotherapy treated patients exhibited significantly smaller total brain 
volume and gray matter volume than reference subjects.  These results suggest that 
structural changes may arise from chemotherapy treatment and may represent permanent 
alterations in the macrostructure of the brain, although the lack of a proper control group 
makes this conclusion tentative at this point.  Koppelman et al. (2012) argue that the 
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volume differences detected by the study were comparable to the effect of approximately 
4 years of age on gray matter loss.  Interestingly, Conroy and colleagues (2013) detected 
a positive correlation between the duration of the post-chemotherapy interval (with a 
sample that was evaluated at an average of 6 years post-treatment) and gray matter 
density in the frontal cortex.  While these results appear to contrast with the findings of 
Koppelman et al. (2012), the difference in post chemotherapy interval between the 
studies may be critical.  Studies that utilize longer intervals may more accurately assess 
and report long-lasting, possibly permanent structural changes within the brain of   
patients treated with chemotherapy, while those studies using shorter intervals may 
produce data more influenced by periods of recovery, like those detected by McDonald et 
al. (2010), that occur shortly after treatment.  These results seem to suggest that cancer 
survivors treated with chemotherapy exhibit temporal patterns of both cognitive changes 
and alterations in brain macrostructure.  Some of these changes have similarities with 
normal aging and have been described as an acceleration of the natural aging process. 
Functional Imaging: In a review of neuroimaging studies, Simo et al. (2013) 
summarized the findings of 8 CRCI fMRI studies.  These fMRI studies identify both a 
subtle pre-treatment impairment in working memory, characterized by higher levels of 
activation within the frontoparietal attentional network (FPN), specifically in the 
prefrontal region, and two temporally distinct periods of altered fMRI activity following 
completion of chemotherapy.  Studies have identified an early period (a few months to 1-
2 years) and a later period (3 years or greater) after treatment in which both fMRI 
activation is altered and impairments on working memory and verbal memory recall are 
detected (McDonald et al., 2012; Kesler et al., 2009).  In the early period, altered 
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neuronal activation is characterized by decreased bilateral frontal activation especially in 
the inferior frontal cortex, which returns to baseline after 1-2 years.  A longitudinal study 
conducted by McDonald and colleagues (2012) provides evidence for this early period, in 
which most early changes in neuronal function detected via fMRI return to baseline after 
1 year.  In addition to this early period of change, other long-term follow-up studies have 
identified a later period of altered functioning that can last for more than 3 years and is 
characterized by hypoactivation of several brain regions including the prefrontal cortex 
(Ruiter et al., 2011), inferior frontal cortex (Kesler et al., 2009; 2011), medial temporal 
lobe (Ruiter et al., 2011), and the posterior parietal cortex (de Ruiter et al., 2011; 
McDonald et al., 2012).  Simo et al. (2013) suggest that this pattern of results may be 
interpreted by an initial alteration in activation that may be compensatory in nature soon 
after treatment, followed by more long-term brain hypoactivation that may be related to 
long-lasting cognitive deficits.   
White Matter Imaging:  Recent studies utilizing both DTI and neuropsychology testing 
have provided evidence that cognitive decline following chemotherapy treatment may be 
related to changes in white matter tracts throughout the brain.  Longitudinal data 
collected by Deprez et al. (2012) prior to chemotherapy and 3-4 years after treatment 
indicates that DTI is sensitive enough to detect disrupted microstructural properties of 
white matter when the corpus callosum and various cortical regions including parietal, 
frontal and occipital regions were compared.  Interestingly, these alterations in white 
matter, characterized by decreased fractional anisotropy, were positively correlated to 
changes in neuropsychological test scores of attention and verbal memory (Deprez et al., 
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2012).  This suggests that chemotherapy induced damage to white matter may be partially 
responsible for cognitive impairments detected in patients. 
 Summarizing the neuroimaging literature, there appears to be more evidence for 
wide spread decreases in both white matter and grey matter throughout the brain 
following chemotherapy treatment than for specific targets of damage.  Nevertheless, 
several studies argue that a handful of cortical areas including: middle frontal gyrus 
(MFG), medial temporal lobe (MTL), and lateral posterior parietal cortex (LPPC), may 
be particularly sensitive to the effects of chemotherapy treatment when utilizing region of 
interest analyses on both functional and structural neuroimaging measures (Inagaki et al., 
2007; Deprez et al., 2011; de Ruiter et al., 2012).  Interestingly, studies that have 
specifically examined the hippocampus for grey matter (Yoshikawa et al., 2005) or white 
matter (Ferguson et al., 2007) alterations following chemotherapy treatment have failed 
to detect any differences when compared to controls.   
Neuroimaging studies like the ones discussed above have certainly helped to 
identify new areas for future research and have provided more objective evidence to 
corroborate patients‘ subjective complaints of CRCI.  Although these studies highlight 
structural changes within the brain following chemotherapy treatment, the mechanisms 
behind these structural alterations are unclear, as is the time course.  Interestingly, it 
appears that chemotherapy treatment may induce both transient and fairly long-lasting 
structural changes within the brain and that some of these changes may represent 
alterations related to recovery processes.  Many researchers within the human literature 
have begun to recognize the importance of establishing animal models of CRCI in order 
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to identify potential underlying physiological and cellular mechanisms (Ahles et al., 
2007; Evenden, 2013). 
Animal Behavioral Models  
  Animal models that are able to further pinpoint factors associated with 
chemotherapy related cognitive deficits have been recognized as necessary for the 
development of the field.  Behavioral models of learning and memory in rodents have 
already been established and are relatively well understood (e.g. autoshaping, contextual 
fear conditioning, Morris water maze, novel object recognition, etc.).  Thus, rats and mice 
provide researchers with an opportunity to reexamine the cognitive decline associated 
with chemotherapy treatment without many of the confounding variables and problems 
discussed throughout the human scientific literature regarding this phenomenon.  In 
particular, animal models have provided researchers with additional opportunities for 
determining which chemotherapy compounds (in isolation and in combination) seem to 
cause cognitive impairment and to elucidate the mechanisms by which these compounds 
may interact with the brain and body to induce cognitive impairment.  By combining 
behavioral study with direct physiological brain and cellular analysis, animal studies are 
providing insight into the behavioral deficits and biological mechanisms associated with 
specific chemotherapy regimes. While animal models of CRCI were once scarce, the 
number of publications has grown in recent years. 
Differences in Drug Class  
One important factor to consider when investigating CRCI is that chemotherapy 
agents vary drastically in chemical structure and physiological properties.  Each class of 
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the following chemotherapy compounds are effective in treating cancer, but do so via 
different molecular mechanisms with the potential to cause different types and degrees of 
cognitive dysfunction.  Although all of following chemotherapy compounds achieve their 
anti-cancer efficacy by interfering with processes involved in cell division and 
proliferation, each drug class does this via a different mode of action.  As such, the ability 
to develop animal models to study these compounds in isolation and in combination 
allows researchers to understand the effects of these different drug classes. 
Alkylating Agents:  Alkylating agents are a class of chemo drug that have the ability to 
alkylate electron-rich atoms such as DNA bases to form covalent bonds.  These bonds 
can result in both intrastrand and interstrand DNA cross-links that prevent the 
transcription and replication of DNA.  Cells that attempt to replicate or repair DNA that 
contain these cross-links usually lead to DNA fragmentation which triggers a state of 
programmed cell death referred to as apoptosis.  Of the alkylating agents, 
cyclophosphamide is the most commonly studied.  Thiotepa is also a commonly 
prescribed alkylating agent used to treat cancer.  Both compounds utilize their ability to 
induce apoptosis in cells via the formation of DNA cross-link produced by covalent 
bonds.  It should be noted that unlike other anti-cancer drugs, alkylating agents are cell 
cycle-independent and can trigger cell death and cause DNA damage regardless of the 
particular cell cycle stage.  This ability may cause alkylating agents to achieve broader 
levels of cellular toxicity that may not be limited to proliferating cells. 
Platinum-based Agents:  Platinum-based agents are referred to as "alkylating-like" as 
they permanently interfere with DNA, like alkylating agents, but do so by allowing a 
platinum atom to bind to DNA bases instead of an alkyl group.  These bonds interfere 
 18 
with DNA in much the same way that alkylating agents do, causing problems with DNA 
transcription and replication and are capable of forming DNA cross-links.  Cisplatin, 
carboplatin and oxaliplatin are all platinum-based chemotherapy agents that are 
commonly prescribed to treat cancer.  Unlike alkylating agents, platinum-based 
compounds are known to cause peripheral neuropathy and their main dose-limiting side 
effect when used as a treatment for cancer is recognized as neurotoxicity.  Several studies 
have examined the effect of platinum-based agents on neurological processes.  These 
studies indicate that platinum-based agents like cisplatin are potentially more toxic to 
neural progenitor cells and oligodendrocytes than they are to cancer cells (Dietrich et al., 
2006) and induce apoptosis (Dietrich et al., 2006; Gopal et al., 2012).  In 2012, Gopal and 
colleagues conducted a study to quantify the neurotoxicity of cisplatin in vitro and found 
cisplatin induced rapid increases in neuronal firing followed by cell death.  These results 
indicate that platinum-based agents like cisplatin are toxic to neurons and capable of 
inducing excitotoxic alterations. 
Antimetabolites:  Antimetabolites are a class of chemical compounds that inhibit normal 
physiological functioning by mimicking the structure of normal human metabolites and 
replacing them with nonfunctional alternatives.  For example methotrexate, which is an 
antifolate drug, competitively inhibits the enzyme dihydrofolate reductase by mimicking 
the structure of folate.  This reduces the synthesis of folic acid which in turn slows the 
production of the nucleoside thymidine, essential for synthesis of DNA and proteins.  In 
most cases, antimetabolites disturb biosynthesis and interfere with the production of 
DNA and RNA causing cell cycle arrest and apoptosis.  Unlike alkylating agents, 
antimetabolites are cell cycle dependent and are only effective during DNA synthesis 
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phase (S-phase) of the cell cycle.  Of the antimetabolites used to treat cancer 
methotrexate and 5-fluorouracil are the most studied. 5-fluorouracil is a pyrimidine 
analog which is incorporated into DNA and RNA of a cell and inhibits the cells ability to 
synthesize DNA and can cause apoptosis.  In addition to these, cytarabine, a cytosine 
deoxyribose analogue, has been studied by a few groups and is also an antimetabolite that 
inhibits the synthesis of DNA.  Studies examining the in vitro and in vivo effects of 
antimetabolites like cytarabine (Dietrich et al., 2006) and 5-fluorouracil (Han et al., 2008) 
indicate that these drugs reduce cell division within the CNS when administered 
systemically, and are more toxic to neural progenitors and oligodendrocytes than to 
cancer cells when directly exposed to cultured cells. 
 Topoisomerase Interactive Agents:  Topoisomerase interactive agents are a class of 
chemical compounds that inhibit or alter normal topoisomerase activity.  In general 
topoisomerases are enzymes that participate in the regulation of DNA topology by cutting 
the phosphate backbone of the DNA, to release tension within the DNA double helix 
structure that occurs during normal DNA replication, which can then be resealed.  While 
it is widely used and researched in combination with other drugs, doxorubicin is one of 
the more commonly studied topoisomerase interactive agents.  Doxorubicin does not 
readily cross the blood-brain barrier and acts by inhibiting the resealing mechanism of the 
enzyme topoisomerase II, by intercalating DNA once it has been cut by the enzyme, and 
subsequently stabilizes the topoisomerase II complex that prevents future DNA 
replication.  In addition to doxorubicin, etoposide is also a topoisomerase interactive 
agent that similarly disrupts the function of topoisomerase II causing DNA strands to 
break. 
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Antimicrotubule Agents:  Antimicrotubule agents are a class of chemical compounds 
that interfere with normal microtubular function which is required to form the mitotic 
spindle necessary for the separation of replicated DNA, a critical component of mitosis.  
Similar to the topoisomerase interactive agent, doxorubicin, many of the commonly 
prescribed antimicrotubule agents do not readily cross the blood-brain barrier.  Of the 
antimicrotubule agents, paclitaxel and docetaxel have been examined within the CRCI 
literature.  
Combination Treatments:  It is fairly common for clinicians to use combinations of 
various chemotherapy compounds to treat breast cancer and other types of cancer.  
Therapeutic strategies for the treatment of cancer that use different classes of compounds, 
or even two slightly different drugs from within the same class, are generally thought to 
be more effective in disrupting cancer cells by utilizing multiple drug mechanisms while 
allowing lower doses that reduce toxicity (Raffa & Tallarida, 2010).  Several animal 
studies have opted to examine the behavioral effects of commonly used clinical regimens 
instead of focusing on particular drugs in isolation.  Many of these researchers argue that 
it may be more important to model and test the effects of these clinically relevant 
combination treatments rather than focusing on individual drugs or class of drug.  Two of 
the most commonly used combination treatments examined within the animal literature 
include a combination of cyclophosphamide and doxorubicin or the widely used clinical 
combination chemotherapy treatment, CMF (cyclophosphamide, methotrexate and 5- 
fluorouracil). 
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Current Gaps in the literature 
A summary of recent animal behavioral findings regarding CRCI is provided in 
Table 1.  Although inconsistency exists across behavioral results presented in Table 1, 
these studies demonstrate that CRCI occurs in animal models across a variety of different 
chemotherapeutic agents in isolation and combination.  In general, these studies have 
provided evidence that all of these compounds are capable of producing behavioral 
deficits in tasks that evaluate cognitive functions related to memory and learning.  
However, the bulk of the animal behavioral data collected to date has focused on 
relatively short time periods, with only 6 of the 37 studies listed in Table 1 utilizing 
assessment intervals greater than 3 months following treatment.  Furthermore, most of 
these studies have only used behavioral tasks that are sensitive to spatial memory 
dysfunction, prioritizing traditionally hippocampal dependent tasks.  This focus on 
hippocampal function has created a rift between animal models of CRCI and the human 
literature, which has emphasized impairments related to disrupted frontal cortical 
function (Evenden, 2013). 
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Table 1: A summary of recent animal behavioral findings regarding CRCI 
 
Drug 
First Author 
and Year 
Dosing Regimen Animals Behavioral Assessment 
Tasks in Which 
Deficits Detected 
Tasks in Which 
No Deficits Were 
Detected 
 Alkylating  
cyclophosphamide 
Acharya 
2015 
weekly x 4 weeks  
100mg/kg, i.p. + 
some got 
hippocampal stem 
cell grafts 
Rats (M) 
Athymic 
nude 
NOR, 
NOR temporal order, 
NOL, 
CFC, 
(all 9-11 weeks a.t.) 
NOR, 
NOR temporal order, 
CFC (impairment for 
contextual memory) 
NOL, 
CFC (cue memory) 
*Animals with 
hippocampal stem cell 
grafts performed like 
saline treated animals 
cyclophosphamide Lee 2006 1 every 4 weeks x 
18 weeks, 
100mg/kg, i.p. 
Rats (F) 
Fischer, 7 
or 18 
months old  
MWM (7 or 29 weeks a.t.),  
Stone Maze (9 weeks or 31 
a.t), 
None MWM, 
Stone Maze 
cyclophosphamide Reiriz 2006 single 8, 40, or 
200mg/kg, i.p. 
Mice (M) 
CD1 
OF, 
PA (24 hrs or 1 week a.t.) 
PA (Impairment, 24 hrs 
r.i.) 
OF, 
PA (Lower dose [8mg/kg] 
or 1 week r.i) 
thiotepa Mondie 
2010 
daily x days, 
10mg/kg, i.p. 
Mice (M)  
C57BL/6 
FST (3,6,8,13,21 weeks 
a.t.),  
TST (8,13,21 weeks a.t.), 
NOR (2,4,8,12,20,30 weeks 
a.t.), 
NOL (2,4,13,20,30 weeks 
a.t.) 
NOR (impairment 8 + 12 
weeks a.t.) 
NOL (impairment 20 
weeks a.t.) 
FST, TST, 
NOR (all other time 
points), 
NOL (all other time points) 
cyclophosphamide Yang 2010 Single 40mg/kg, 
i.p. 
Mice (M) 
ICR 
OF (12hrs and 10 days a.t.),  
PA (12hrs and 10 days a.t.),  
NOR (12hrs and 10 days 
a.t.) 
PA (impairment 12 hrs 
a.t.), 
NOR (impairment 12 hrs 
a.t.) 
OF, 
PA (10 days a.t.), 
NOR (10 days a.t.) 
cyclophosphamide Christie 
2012 
weekly x 4 weeks, 
50mg/kg, i.p. 
Rats (M) 
Athymic 
nude 
NOL (1 week a.t.), 
CFC (2 weeks a.t.) 
NOL (impairment 5 min 
r.i.) 
CFC (impairment for 
contextual memory) 
NOL (24 hrs r.i.), 
CFC (cue memory) 
Platinum-based 
oxaliplatin 
Fardell 2012 single 12mg/kg, 
i.p. 
Rats (M) 
Wistar 
NOR (14 days a.t., 1 hr r.i.), 
MWM (21 days a.t.), 
CFC (28 days a.t.) 
NOR (impairment 14 
days a.t.), 
CFC (impairment for 
contextual memory) 
MWM, 
CFC (cue memory) 
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oxaliplatin Sharpe 
2012 
single 12mg/kg, 
i.p.  
Rats (M) 
Sprague-
Dawley 
CFC (10 days a.t.), 
CFC extinction (13 days 
a.t.), 
CFC renewal (15 days a.t.) 
*new context 
CFC renewal 
(impairment for renewal 
in novel context) 
CFC (No Impairment in  
cued or contextual tests, 
conditioning or extinction) 
Antimetabolites 
methotrexate 
Seigers 
2008 
single 250mg/kg, 
i.v. 
Rats (M) 
Wistar 
MWM (3 weeks a.t.),  
NOR (4 weeks a.t., 1 hr r.i)  
MWM (impairment 3 
weeks a.t) 
NOR (Impairment 4 
weeks a.t., 1hr r.i.) 
MWM (all other measures) 
methotrexate Seigers 
2009 
single 250mg/kg, 
i.v. 
Rats (M) 
Wistar 
MWM (training prior to 
treatment tested 1 week 
a.t.), 
CFC (training prior to 
treatment tested 1 month 
a.t.) 
MWM (impairment 1 
week a.t. for time spent 
in target quadrant)  
CFC (impairment 1 
month a.t.) 
None 
methotrexate Fardell 2010 single 250mg/kg, 
i.p. 
Rats (M) 
Wistar 
MWM (2 weeks + 8 months 
a.t.),  
NOR (11,95,254 days a.t.,1 
hr r.i + 255 days a.t. with 2 
hrs r.i.), 
Go-No/Go Task (174 days 
a.t.) 
MWM, (impairment 8 
months a.t.), 
NOR, (11+95 days a.t. 
with 1hr r.i., at 255 days 
a.t. with 2hrs r.i,) 
Go-No/Go Task 
(impairment  learning)  
MWM, (2 weeks a.t.), 
NOR, (254 days a.t. with 
1hr r.i.) 
methotrexate Li 2010 Acute: single 
250mg/kg i.p; 
Chronic: weekly x 
10 weeks, 
1mg/kg, i.p. 
Rats (M) 
Long 
Evans 
OF (3 days a.t.), 
NOL (1 week a.t., 5 or 
10min r.i.), 
NOR (1 week a.t., 2hrs r.i.) 
NOL (impairment 1 week 
a.t., 5min r.i. for both 
acute and chronic) 
OF, 
NOL ( week a.t.,10min 
r.i.), 
NOR 
methotrexate Lyons 2011 weekly x 2, 
75mg/kg, i.v. 
Rats (M) 
Listar 
NOL (3 weeks a.t., 15min 
r.i.) 
NOL None 
methotrexate or  
5-fluorouracil 
Foley 2008 single i.p. 15mins 
prior to task, 
varied dose: MTX 
(1 to 32mg/kg) or 
5-FU (3 to 
75mg/kg) 
Mice (M) 
Swiss 
Webster 
Autoshaping task 
(involved learned rewarded 
response patterns) 
Autoshaping task,(high 
dose of 5-FU only during 
retrieve a previously 
learned response 2 days 
a.t.) 
MTX and lower doses of 
5-FU failed to cause 
impairments on task 
acquisition or 
retention/retrieval 
Table 1: Continued 
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methotrexate or  
5-fluorouracil 
Walker 2011 weekly x 3 weeks. 
MTX (3.2 or 
32mg/kg) or 5-FU 
75 mg/kg, i.p. last 
injection 15mins 
prior to task 
Mice (M) 
Swiss-
Webster 
Autoshaping task 5-FU alone (impairment 
on acquisition and 
retention) 
MTX (no impairments) 
methotrexate or  
cytarabine 
Bisen-Herch 
2013 
3 i.p. injections 
PD 14 15 and 16, 
of MTX (1 or 2 
mg/kg) or Ara-C 
(10 or 20 mg/kg) 
Mice (M+F) 
Swiss-
Webster 
Autoshaping task, 
NOR (1hr r.i.), 
Conditional discrimination 
task, 
(all done 19 days a.t.) 
Autoshaping task* 
(impairment for retention 
and acquisition),  
NOR*, Conditioned 
Discrimination 
(impairment in 
acquisition), 
*only found with higher 
doses 
no significant differences 
were found between M 
and F mice, 
Lower doses 
methotrexate Yang 2012 Some Tumor-
Bearing* single 
40mg/kg, i.p. 
Mice (F) 
C3H/HeN 
OF, TST, PA 
(all done 24 hrs a.t.) 
TST (more depressive 
like behavior for tumor-
bearing as well MTX 
alone or in addition), 
PA (impairment caused 
by MTX 24hrs a.t.) 
OF 
5-fluorouracil Mustafa 
2008 
5 over 12 days, 
20mg/kg, i.v. 
Rats (M) 
Listar 
NOL (5 min r.i.) NOL (impairment in 
mean exploratory times 
of novel location but not 
in preference index 
scores) 
None 
5-fluorouracil ELBeltagy 
2010 
6 over 2 weeks,  
20mg/kg, i.v. + 
some animals 
received 
10mg/kg/d 
Fluoxetine in 
drinking water 
Rats (M) 
Listar 
NOL  (1 day a.t.), 
CFC (1 day a.t.) 
NOL  (1 day a.t.), 
CFC (1 day a.t.) 
NOL (animals treated with 
5-FU+Fluoxetine showed 
no impairment) 
5-fluorouracil Krynetskiy 
2013 
3 over 24hrs, 
75mg/kg, i.p. 
Mice (M) 
Swiss 
Webster 
Autoshaping task (1 day 
a.t., 24hrs r.i.) 
Autoshaping 
task*(impairment for 
retention and acquisition 
on 24 hrs r.i),  
Autoshaping task (initial 
acquisition was 
unaffected) 
Table 1: Continued 
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5-fluorouracil Mahoney 
2013 
daily x 5 days, low 
(20mg/kg), 
medium 
(40mg/kg), or high 
(60mg/kg) i.p. 
Mice (M+F)  
C57BL/6 
and MCP-1 
-/- Mice 
Measure of Fatigue: 
Voluntary Wheel Running 
(collected for 15 days post-
treatment), 
Grip strength (days 5 and 
14 a.t.)  
Dose dependent 
reductions in voluntary 
Wheel Running 
Grip strength 
5-fluorouracil Fremouw 
2012 
weekly x 3 weeks, 
100 mg/kg, i.p. 
Mice (M)  
C57BL/6 
CFC (1 weeks a.t.), 
CFC remote (2 weeks a.t., 
40 days r.i.), 
NOR (2 weeks a.t., 1 hr r.i.) 
None All testing: 
CFC + CFC remote, 
NOR 
cytarabine Fremouw 
2012 
daily x 5 days, 
275mg/kg, i.p. 
Mice (M)  
C57BL/6 
MWM Recent (42 days a.t., 
24 hrs r.i.), 
MWM Remote (42 days a.t., 
30 days r.i.)  
None All testing: 
MWM recent + remote 
memory, 
Acquisition, 
cytarabine Li 2008 daily x 5 days, 
400mg/kg, i.p. 
Rats (M) 
Sprague-
Dawley 
MWM (1 week a.t., 24 hrs 
r.i. and 30 days r.i.), 
MWM remote memory 
(impairment on 30 days 
r.i.) 
MWM recent memory (no 
impairment on 24hrs r.i.)  
Topoisomerase 
Interactive  
doxorubicin  
Christie 
2012 
weekly x 4 weeks, 
2mg/kg, i.p. 
Rats (M) 
Athymic 
nude 
NOL (1 week a.t.), 
CFC (2 weeks a.t.) 
NOL (impairment 5 min 
r.i.) 
CFC (impairment for 
contextual memory) 
NOL (24 hrs r.i.), 
CFC (cue memory) 
doxorubicin Fremouw 
2012 
weekly x 3 weeks, 
4mg/kg, i.p. 
Mice (M)  
C57BL/6 
CFC (1 weeks a.t.), 
CFC remote (2 weeks a.t., 
40 days r.i.), 
NOR (2 weeks a.t., 1 hr r.i.) 
None All testing: 
CFC + CFC remote, 
NOR 
doxorubicin  Liedke 2009 single 0.5, 2 or 
8mg/kg, i.p. either 
30mins before 
training or after 
30mins  
Rats (M) 
Wistar 
PA treatment before training 
(3hrs, 24hrs and 7 days r.i.) 
PA treatment after training 
(3hrs, 24hrs and 7 days r.i.) 
PA treatment before 
training (24hrs and 7 
days r.i.) 
PA treatment before 
training, (no impairment in 
3hrs r.i.), 
PA treatment after training  
etoposide  Wood 2006 Some Tumor-
Bearing* 5 over 2 
weeks 50mg/kg, 
i.p. 
Mice (F) 
C57BL/6 
Voluntary Wheel Running 
(before and during 
treatment) 
Reductions in voluntary 
Wheel Running, due to 
chemo and/or tumor  
None 
Antimicrotubule 
paclitaxel 
Boyette 
2009 
1 every other day 
x 12 days 1mg/kg 
i.p. 
Rats (M) 
Long 
Evans 
MPW (tested  throughout 
treatment for 20 days ), 
5CSRTT (tested  during 
treatment for 20 days ) 
"peripheral neuropathy" 
MPW (threshold 
decreased within 24hrs) 
5CSRTT (no impairments)  
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docetaxel Fardell 2013 weekly x 3 weeks,   
6mg/kg or 
10mg/kg i.p.; or 
single 10mg/kg 
i.p. 
Rats (M) 
Wistar 
MWM (2 weeks a.t, 24hrs or 
100 days r.i.), 
NOR (1 or 2 weeks a.t., 
2hrs or 100 days r.i.), 
MPW (12 or 120 days a.t) 
NOR (trends for 
impairment at both time 
points), 
MPW (impairment 12 
days a.t) 
MWM (no impairment but 
poor control performance) 
MPW (no impairment 120 
days a.t) 
Combination 
Treatments 
methotrexate and  
5-fluorouracil 
Gandal 
2008 
weekly x 4 weeks, 
High: MTX 
(37.5mg/kg )+5-
FU(75mg/kg), i.p. 
Low: MTX 
(18.75mg/kg)+5-
FU(37.5mg/kg), 
i.p. 
Mice (M) 
C57BL/6 
NOR (2 weeks a.t., 24hrs 
r.i.), 
CFC (28 day a.t.), 
EEG auditory gating (during 
treatment) 
EEG Auditory Gating 
(Less gating during 
treatment) 
NOR, 
CFC 
doxorubicin and 
cyclophosphamide 
Fremouw 
2012 
weekly x 3 weeks, 
4mg/kg Dox + 
80mg/kg Cyclo 
i.p. 
Mice (M)  
C57BL/6 
CFC (1 weeks a.t.), 
CFC remote (2 weeks a.t., 
40 days r.i.), 
NOR (2 weeks a.t., 1 hr r.i.) 
None All testing: 
CFC + CFC remote, 
NOR 
doxorubicin and 
cyclophosphamide 
Konat 2008 weekly x 4 weeks 
Dox (2.5mg/kg) + 
Cyclo (25mg/kg), 
i.p.; one group 
given NAC 
200mg/kg 3 per 
week x 4 weeks 
  
Rats (F) 
Sprague-
Dawley 
OF, 
PA (2 days a.t, 24hrs r.i.) 
PA (impaired 24hrs 
memory ) 
OF, 
PA (*NAC treatment fully 
prevented) 
doxorubicin and 
cyclophosphamide 
Macleod 
2007 
weekly x 3 weeks 
Dox (4mg/kg) + 
Cyclo (40mg/kg) 
i.v. 
Rats (F) 
Ovariectom
ized 
Sprague-
Dawley 
CFC (1 week a.t., 24hrs r.i.) CFC (impairment for 
contextual memory) 
CFC (cue memory) 
cyclophosphamide, 
methotrexate and  
5-fluorouracil 
Briones 
2011 
weekly x 4 weeks 
CMF: Cyclo 
(40mg/kg) + MTX 
(37.5mg/kg) + 5-
FU (75mg/kg), i.p.  
Rats (F) 
Wistar 
MWM (2 weeks a.t.), 
MWM cued discrimination 
task 
MWM (impaired 
acquisition and memory), 
MWM cued 
discrimination task (more 
errors) 
None 
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cyclophosphamide 
and 5-fluorouracil 
Long 2011 3 monthly 
Cyclo (50mg/kg) 
+ and 5-FU 
(75mg/kg) 
last 2 doses: 
[Cyclo (75mg/kg) 
+ 5-FU 
(120mg/kg)] i.p. 
Rats (M) 
Fischer-
344 
Remote CFC (trained b.t., 
tested 120 days a.t.), 
MWM (130 days a.t.), 
Stone Maze (150 days a.t.) 
None Remote CFC, 
MWM, 
Stone Maze 
methotrexate and 
cytarabine 
Bisen-Herch 
2013 
3 i.p. injections 
PD 14 15 and 16, 
of (1 mg/kg MTX 
+ 10mg/kg Ara-C) 
or  
(2mg/kg MTX and 
20mg/kg Ara-C) 
Mice (M+F) 
Swiss-
Webster 
Autoshaping task, 
NOR (1hr r.i.), 
Conditional discrimination 
task, 
(all done 19 days a.t.) 
Autoshaping task 
(impairment for retention 
and acquisition),  
NOR, 
Conditioned 
Discrimination 
(impairment in acquisition 
*and memory with higher 
dose), 
no significant differences 
were found between M 
and F mice 
oxaliplatin and 5-
fluorouracil 
Fardell 2012 Single  
 OX 8mg/kg + 5-
FU 75mg/kg i.p., 
[half got running 
wheels for 4 
weeks] 
Rats (M) 
Wistar 
NOR (14 + 40 days a.t., 1hr 
+ 2hrs r.i.), 
MWM (21 days and 54 a.t.), 
CFC (28 days a.t.) 
NOR (14 days a.t., and 
40 days a.t., 2hr*), 
MWM (54 days a.t.*) 
CFC (impairment for 
contextual memory) 
MWM (21 days a.t.), 
NOR (40 days a.t., 1hr), 
CFC (cue memory) 
*Running Wheels 
prevented impairments in 
MWM + NOR 
methotrexate and 
5-fluorouracil 
Walker 2011 weekly x 3 weeks.  
3.2 or 32mg/kg 
MTX + 7 mg/kg 5-
FU, i.p.; last 
injection 15mins 
prior to task 
Mice (M) 
Swiss-
Webster 
Autoshaping task Autoshaping task 
(impairments in 
acquisition and retention) 
*lower dose of MTX with 
5-FU was more 
impairment 
*Higher doses of MTX 
caused less impairment  
methotrexate and 
5-fluorouracil 
Winocur 
2006 
weekly x 3 weeks 
MTX 37.5mg/kg  
+ 5-FU 75mg/kg, 
i.p. 
Mice (F) 
BALB/c 
Modified MWM tests 1 week 
a.t.: 
Standard, 
Cued Memory, 
NMTS, 
DNMTS (60,120,240 sec 
r.i.), 
Black-White Discrimination 
NMTS (small increase in 
errors), 
DNMTS (240 sec r.i.), 
MWM standard test, 
MWM test Cued Memory, 
NMTS (latency), 
DNMTS (60, 120 sec r.i.), 
Black-White 
Discrimination 
Table 1: Continued 
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8 
methotrexate and 
5-fluorouracil 
Winocur 
2011 
weekly x 4 weeks 
MTX 50mg/kg  + 
5-FU 75mg/kg, 
i.p.; some given 
Donepezil 
3mg/kg/d in water 
during treatment 
Mice (F) 
BALB/c 
Modified MWM tests 1 week 
a.t.: 
Standard, 
Cued Memory, 
NMTS, 
DNMTS (60,120,240 sec 
r.i.), 
Standard (impaired 
spatial memory) 
NMTS, 
DNMTS (all delays) 
MWM test Cued Memory, 
Donepezil reduced the 
deficits in all tasks 
methotrexate and 
5-fluorouracil 
Winocur 
2012 
weekly x 3 weeks 
MTX 37.5mg/kg  
+ 5-FU 50mg/kg, 
i.p. 
Mice (F) 
BALB/c 
Modified MWM tests 24hrs 
and 3 months a.t.: 
Standard, 
Cued Memory, 
NMTS, 
DNMTS (60, 120, 240 sec 
r.i.), 
Conditioned associative 
learning, 
Brightness discrimination 
learning 
Standard (impaired 
spatial memory at both 
time points), 
NMTS (both time points), 
DNMTS (both time points 
all delays), 
 Conditioned associative 
learning (impaired 
learning), 
Brightness discrimination 
learning (impaired 
learning) 
MWM test Cued Memory, 
methotrexate and 
5-fluorouracil 
Winocur 
2015 
weekly x 3 weeks 
MTX 37.5mg/kg  
+ 5-FU 50mg/kg, 
i.p. 
Rats (F) 
Long 
Evans 
Modified water T maze test: 
low inference, 
high inference, 
high inference (memory 
impairment) 
high inference (no 
learning impairment), 
low inference (no learning 
or memory impairment) 
 
Abbreviations – Ara-C: cytarabine; Cyclo: cyclophosphamide; CMF: combination of cyclophosphamide, methotrexate and 5-
fluorouracil; Dox: doxorubicin; MTX: methotrexate; NAC: N-acetyl cysteine; OX: oxaliplatin; 5-FU: 5-fluorouracil; CFC: contextual 
fear conditioning; 5CSRTT: five-choice serial-reaction time task;  FST: forced swim test; NOL: novel object location; NOR: novel 
object recognition; MPW: mechanical paw withdrawal threshold; MWM: Morris water maze; OF: open field test; PA: passive 
avoidance conditioning; NMTS: non-matching to sample; and DNMTS: delayed non-matching to sample; TST: tail suspension test; 
a.t.: after treatment; i.p.: Intraperitoneal injection; i.v.: Intravenous injection; r.i.: retention interval.
Table 1: Continued 
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Only 8 of the 37 studies listed in Table 1 have used tasks that assess animal 
behaviors that may be related to frontally mediated functions such as response inhibition, 
behavioral spontaneity, and habituation.  These tasks include: autoshaping paradigms 
(Foley et al., 2008; Walker et al., 2011; Bisen-Herch et al., 2013; Krynetskiy et al., 2013), 
the 5-choice serial reaction time task (5CSRTT) (Boyette et al., 2009), and a non-
matching-to-sample (NMTS) variant of the Morris water maze (Winocur et al., 2006; 
2011; 2012). Thus, the current animal behavior literature concerned with CRCI faces two 
major problems in further elucidating the phenomenon: too much focus on a single 
cognitive system, and insufficient long-term designs.  These problems have made it 
difficult for researchers to make progress understanding the cognitive and neurological 
deficits caused by chemotherapy treatment and have limited the translational insight that 
the current animal literature can provide to the human condition of chemo-brain. 
Behavioral Tasks:  Much of the animal behavior literature has focused on tasks thought 
to be dependent on hippocampal function.  The initial emphasis on these hippocampal 
based tasks was driven by the knowledge that chemotherapy agents disrupt proliferating 
cells, and as such, may disrupt neuronal structures in which neurogenesis takes place, like 
the hippocampus.  Furthermore, behavioral models of learning and memory in rodents 
that are sensitive to hippocampal damage are relatively well established.  Commonly 
studied hippocampal dependent behavioral tasks in the literature include: novel object 
location, Morris water maze, contextual fear conditioning, and passive avoidance 
conditioning.  These tasks are commonly used because they are thought to assess an 
animal‘s ability to successfully learn contextual spatial cues and access spatial memory 
during training and testing. 
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For instance, novel object location relies on rodents‘ natural tendency to approach 
and explore novelty in order to assess whether a rodent remembers the previous location 
of an object that has been moved to a novel location.  Tasks like the Morris water maze, 
contextual fear conditioning, and passive avoidance conditioning, all rely on rodents‘ 
desire to escape or avoid an aversive stimulus by correctly remembering spatial and 
contextual cues.  Chemotherapy compounds appear capable of producing deficits in both 
learning and memory across all of these tasks when tested shortly after treatment and, as 
such, are thought to impair hippocampal function, potentially by interfering with 
neurogenesis related processes (e.g., Konat et al., 2008; Seigers et al., 2009; Yang et al., 
2010; Briones et al., 2011; Fardell et al., 2012; Christie et al., 2012) 
There have only been 8 attempts to date, within the animal literature to explore 
cognitive domains outside spatial memory.  Of these studies, those that utilize 
autoshaping paradigms are the most common and produce the most reliable, albeit subtle, 
deficits in acquisition and latency to retrieve previously learned responses (Foley et al, 
2008; Walker et al., 2011; Bisen-Herch et al., 2013; Krynetskiy et al., 2013).  In addition, 
Boyette and colleagues (2009) ran the only study within the field that attempted to 
evaluate CRCI in animals with the 5-choice serial reaction time task (5CSRTT).  The 
5CSRTT is an operant paradigm in which animals must attend to a randomly presented 
visual stimuli and quickly respond (within 0.5 sec.) with nose-poke response in order to 
receive a reinforcement.  The task is thought to be sensitive to changes in attention 
systems, executive function and information processing speed.  Finally, Winocur et al. 
(2006; 2011; 2012) argue that they have been able to detect impairments using a 
modification of the standard Morris water maze, in which animals must learn a NMTS 
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rule in order to correctly use a visual cue to escape the maze.  The addition of the NMTS 
rule is posited by Winocur and collegeues (2006) to be ―highly sensitive to frontal-lobe 
dysfunction but not typically affected by damage to the hippocampus‖ (p. 68).   
Together these studies represent a small minority of the tasks used within animal 
behavior models of CRCI.   When examined as a whole, the behavioral tasks presented in 
Table 1 demonstrate that the animal behavior literature currently suffers from a lack of 
variety.  The overwhelming focus on hippocampal function has resulted in a failure to 
investigate the effects of chemotherapy compounds on other cognitive systems in 
animals, including those that have already been highlighted within the human literature. 
Lack of Long-Term Designs:  31 of the 37 studies listed in Table 1 have examined the 
effects of chemotherapy compounds only out to 3 months after treatment, with the vast 
majority of these only investigating effects up to 1 week after treatment.  Although short-
term impairments are meaningful, they provide little insight into the possible long-term 
effects of these compounds, recognized as so important in the human literature.  
Furthermore, deficits detected shortly after treatment are confounded with sickness like 
effects that are known to occur in rodents shortly after chemotherapy administration 
(Wood et al., 2006).  Of the studies listed in Table 1, only 6 have investigated the 
behavior of animals more than 3 months after receiving treatment and only half those 
studies (Fardell et al., 2010; Mondie et al., 2010; and Winocur et al., 2012) found any 
detectable deficits while the other half failed to identify any impairments in any 
behavioral measures (Lee et al., 2006; Fardell et al., 2013; Long et al. 2011).  The only 
interesting commonality seen in 2 of the 3 studies that found long-term deficits were that 
both Fardell et al. (2010) and Winocur et al. (2012) found deficits in the Morris water 
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maze after animals were administered methotrexate.  This suggests that methotrexate may 
be a particularly effective disruptor of hippocampal function at longer time intervals 
compared to other agents and combinations of agents that were not able to produce these 
effects.  Furthermore, these results stress the need for better extended profiling of these 
compounds and their long-term capacity to disrupt cognitive function.  More long-term 
designs are needed to confirm these limited cognitive findings and to help determine if 
CRCI detected shortly after treatment, may persist for longer or reflect permanent loss of 
function.   
Inconsistent Results:  A cursory glance at the results in Table 1 reveal a considerable 
amount of inconsistency across the behavioral findings of the studies listed.  For instance, 
when comparing studies that examined the effects of methotrexate on rats assessed with 
novel object recognition, Seigers et al. (2008) found impairment while Li et al. (2010) did 
not.  Both studies administered a single dose of 250 mg/kg methotrexate to male rats that 
were approximately 12 weeks of age and both studies assessed memory function with a 
novel object recognition test.  While these studies are quite similar they were conducted 
with different rat strains, as Seigers et al. (2008) used Wistar rats and Li et al. (2010) used 
Long Evans rats, and the exact timing of assessment differed with Seigers et al. (2008) 
testing animals 4 weeks after treatment while Li et al. (2010) assessed animals 1 week 
after treatment.  The contrasting results of these two studies demonstrate the sensitivity of 
behavioral tests like novel object recognition to experimental variability. 
  There are numerous theoretical sources for this variance within the behavioral 
data.  In the studies listed in Table 1, the exact timing and dose used during treatment can 
vary greatly even when examining studies using the same drug, within the same species.  
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While it is common to justify the choice of dosing regimen, these differ based on the 
goals unique to each study.  Dosing regimens differ based on desire to mimic clinical 
paradigms (Long et al., 2011), the use of a maximally tolerable dose determined by pilot 
data (Seigers et al., 2008), the use of a reference dose based on pharmacokinetics to find 
dose-dependent effects (Liedke et al., 2009), or even the use of a specific dose that 
replicates previous studies (Fardell et al., 2010).  Regardless of the reason, these 
decisions can drastically alter the behavioral results making comparisons and 
interpretations of contrasting results difficult.  Typical variations seen within the 
literature include: the use of multiple low dose injections, single high dose injections, 
multiple injections over a long period (month or greater), and multiple injections over a 
short period (several days to a week).  Furthermore, the animal literature regarding CRCI 
has generally not addressed the issue that toxicity and tolerance of chemotherapy agents 
can vary drastically as a function of circadian rhythm, further compounding variance 
among studies (Focan, 1995; Borniger et al., 2017; although see Fremouw et al., 2012a 
and 2012b).  While these problems are not unique within the field of 
neuropsychopharmacology, it represents a significant barrier when determining which 
chemotherapeutic agents may cause cognitive dysfunction in animal models.  
Suggested Biological Targets and Mechanisms 
One strength of animal models is the ability to design experiments that directly 
explore the neurobiological mechanisms that are responsible for CRCI.  This approach 
allows researchers a different perspective that focuses on the neurobiological changes 
following chemotherapy treatment.  By understanding and mapping out these changes 
researchers may be able to make sense of the inconsistent behavioral results obtained in 
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animal models to date.  The identification of cellular targets and processes that underlie 
these negative alterations are important for the translation of research accomplishments in 
the field into clinical application.  Once these mechanisms have been identified and 
understood, clinicians will be better able to reduce or even prevent the cognitive 
impairments seen in patient populations. 
Potential Cellular Targets 
White Matter Damage:  While neuronal damage and related processes have been the 
primary subject of many research efforts, researchers in both the animal and human 
literature have recognized the importance of white matter changes following 
chemotherapy treatment.    White matter plays a critical role in regulating neuronal 
impulse conduction and synchronizing communication across neuronal networks 
(Madden et al., 2012).  In addition to these functions, myelinating glia appear to have a 
variety of other activities that support normal neuronal activity, including the production 
of proteins that constrain nervous system plasticity (Fields et al., 2008).  Many 
researchers have suggested that white matter tracts throughout the CNS may be 
vulnerable to chemotherapeutic insult following treatment through direct toxicity, 
damage via oxidative stress, or inflammatory disturbance.  
Interestingly, recent human research has suggested that age-related cognitive 
difficulties may be due to differences in structural integrity of white matter (Madden et 
al., 2012).  In a review by Madden et al. (2012), it is suggested that normal cognitive 
decline associated with aging may be related to white matter integrity and a decrease in 
efficiency of communication among networks important for fluid cognitive abilities.  
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Some have made the theoretical leap that the effects of aging on cognitive systems may 
be similar to the effects of chemotherapy treatment.  In other words, chemotherapy may 
cause accelerated aging of cognitive systems and negatively impact white matter integrity 
throughout the CNS.  As previously discussed, evidence in support of this theory does 
exist within the human literature.  For example, the DTI studies of Deprez et al. (2011, 
2012, and 2013) suggest that chemotherapy compounds can disrupt white matter integrity 
and result in cognitive impairments in attention, psychomotor speed, and memory that 
can last up to 5 months.  de Ruiter and colleagues (2012) have even reported that changes 
in white matter integrity following chemotherapy treatment can be detected up to 10 
years after treatment when compared to non-chemotherapy treated patients.    
Within the animal literature, only a handful of studies have examined the role of 
white matter and chemotherapy related insult.  Han et al. (2008) found that 5-fluorouracil 
is toxic to both immature and mature oligodendrocytes in vitro.  Furthermore, when 
administered in vivo, 5-fluorouracil resulted in loss of myelin basic protein and 
cellularity within the corpus callosum up to 56 days after completion of chemotherapy 
treatment.  In addition to these findings, Han reported increased auditory brainstem 
response (ABR) inter-peak latencies detected at 14 and 56 days following completion of 
chemotherapy treatment.  The authors argue that these results represent compromised 
functional integrity of white matter tracts within the CNS due to chemotherapy treatment.  
Recent follow-up experiments within our lab have revealed similar short-term deficits (up 
to 14 days after treatment) in ABR inter-peak latencies following treatment with 5-
fluorouracil, cyclophosphamide or doxorubicin in mice.  ABR analysis of white matter 
function at 56 days and 6 months post-treatment failed to detect any impairment.  
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Subsequent tissue analysis was conducted utilizing black gold II, an aurohalophosphate 
complex, which is selectively absorbed into myelinated axons and used to produce high 
contrast images of myelin in tissue samples.  Results of histochemical tissue analysis with 
black gold II were consistent with the ABR data, showing no deficits in myelin integrity 
at 56 days and 6 months post-treatment.  However, black gold II staining of tissue 
collected 14 months post-treatment suggested long-term, possibly permanent 
demyelination had occurred in animals treated with either 5-fluorouracil or a combination 
of cyclophosphamide and doxorubicin.  Unfortunately, ABRs could not be collected from 
animals at this point due to hearing loss across the entire sample.  Taken together, these 
studies provide evidence that white matter tracts may be susceptible to chemotherapeutic 
insult shortly after treatment and, for some individuals, may reemerge after initial 
recovery as a persistent loss in white matter integrity with age.  This pattern of damage to 
white matter detected in animal models is consistent with human imaging studies that 
indicate similar early transient impairments, followed later, by more persistent alterations 
in brain structure and function (Simo et al., 2013; Deprez et al., 2012).  
While animal research investigating the association between white matter 
integrity and chemotherapy related cognitive impairment is limited, there are many well 
established animal models designed to explore the role of white matter damage in 
cognition, in particular its function in multiple sclerosis (MS).  These models provide 
both behavioral and physiological benchmarks by which chemotherapy related white 
matter damage may be compared to and assessed.  The most prominent rodent models are 
experimental autoimmune encephalomyelitis (EAE) and cuprizone-induced toxic 
demyelination.  Both of these established experimental animal models are thought to 
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approximate and produce many of the same pathological features of MS including: 
inflammation, demyelination, and axonal loss (Skripuletz et al., 2008; Constantinescu et 
al., 2011; Kurkowska-Jastrzębska et al., 2013).  Furthermore, several researchers have 
documented deficits in learning and memory following demyelination using these 
techniques in tasks such as the Morris water maze (D‘Intino et al., 2005; Kurkowska-
Jastrzębska et al., 2013) and the Y maze (Xiao et al., 2008; Makinodan et al., 2009).  
Both the EAE and cuperizone models may provide useful comparison data to determine 
if chemotherapy treatments cause similar toxicity induced demyelination and white 
matter damage.  
 Currently it is unclear whether significant differences in susceptibility to 
chemotherapy related damage exist between white matter and neurons.  Gliogenesis, glial 
inflammation, and oxidative stress could all represent mechanisms by which white matter 
may be damaged.  It is currently unknown to what degree white matter damage may 
explain CRCI.  Many researchers posit that white matter damage may be a key 
mechanism responsible for the phenomenon.  While extended studies that investigate 
long-term changes in white matter integrity following chemotherapy treatment are still 
lacking, results from several animal models and human DTI studies seem to indicate that 
white matter damage may persist long after chemotherapy treatment has ended.  
Chemotherapy induced damage to white matter seems to represent a plausible cellular 
target for CNS damage that maps on well to the both the types of cognitive problems 
being reported and the persistent nature of some of these side effects. 
Proliferative Cell Vulnerability:  Cellular processes involved in mitosis and the 
proliferation of cancer cells are the primary targets of the majority of chemotherapeutic 
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compounds used to treat cancer.  Unfortunately these compounds are not selective and 
can theoretically affect proliferative cells in both the PNS and CNS.  In addition, 
populations of both neurons and glial cells within the CNS are known to proliferate.  As 
such, they may both be vulnerable to insult from chemotherapeutic compounds or their 
metabolites.  The process of neuronal proliferation referred to as neurogenesis is known 
to occur within the hippocampus and other select regions of the adult brain.  New neurons 
within the subgranular zone (SGZ) of the dentate gyrus (DG) that originate from dividing 
populations of adult neural stem cells may eventually migrate to the granule cell layer 
and integrate into existing neural networks after several weeks (Song et al., 2012).  While 
some of these newborn neural progeny successfully mature, a significant percentage are 
eliminated through normal processes of apoptosis and microglia-mediated phagocytosis 
(Song et al., 2012).  Many researchers suspect that proliferating neurogenic cells within 
the CNS may be particularly susceptible to insult and a likely target for cellular damage 
within the brain following chemotherapy treatment.  
A Variety of Chemotherapy Drugs Decrease Neurogenesis:  Research conducted 
in vitro suggests that a variety of chemotherapy compounds may be more toxic to neural 
progenitor cells and oligodendrocytes than to cancer cells when administered directly to 
the cells (Dietrich et al., 2006; Han et al., 2008).  In addition to being toxic, 
chemotherapy compounds that enter the brain may cause significant disruptions to the 
cellular processes that underlie neurogenesis, including proper developmental 
differentiation and successful maturation.  Several studies have investigated neurogenesis 
levels following chemotherapy treatment and have found that a variety of chemotherapy 
compounds can negatively impact neurogenesis within the hippocampus of rodents 
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including: cyclophosphamide (Yang et al., 2010; Janelsins et al., 2010; Christie et al., 
2012), thiotepa (Mondie et al., 2010), BCNU (Dietrich et al., 2006), 5-fluorouracil (Han 
et al., 2008; Mustafa et al., 2008; Janelsins et al., 2010), methotrexate (Seigers et al., 
2008; 2009; Lyons et al., 2011; Yang et al., 2012), cytarabine (Dietrich et al., 2006), 
doxorubicin (Christie et al., 2012; Janelsins et al., 2010), paclitaxel (Janelsins et al., 
2010), cisplatin (Dietrich et al., 2006), and a clinical combination CMF (Briones et al., 
2011).  Taken together, these studies demonstrate that every chemotherapy drug class has 
the capacity to decrease neurogenesis.  To quantify decreases in neurogenesis, studies 
employ immounohistochemical methodology and either Ki-67 or BrdU antibodies as 
markers for cellular proliferation.  Ki-67 is an endogenously produced protein that is 
strictly associated with cellular proliferation.  Unlike Ki-67, BrdU is an exogenous 
marker of proliferation.  BrdU is a synthetic nucleoside and a structural analog of 
thymidine that can be incorporated into the DNA during replication as a thymidine 
substitute, and can later be detected via BrdU specific antibodies.  Antibodies for Ki-67 
and BrdU can be used to create high contrast immounohistochemical staining to label 
proliferating cells within the hippocampus.  While results from these studies report 
significant reductions in Ki-67 and BrdU positive cells following chemotherapy 
treatment, the causes of these reductions remains unclear.   
When examining the results of studies that have assayed both apoptosis and 
proliferation, different patterns of results emerge suggesting that some chemotherapy 
compounds, even compounds from within the same drug class, may induce apoptosis in 
these new neurons while others reduce proliferation without causing cell death.  For 
instance, Janelsins et al. (2010) found decreases in BrdU positive cells within the DG of 
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animals 2 days after completion of treatment with cyclophosphamide, doxorubicin, 5-
fluorouracil, or paclitaxel without significant increases in apoptotic BrdU labeled cells.  
In contrast, Dietrich et al. (2006) found that animals treated with BCNU or cisplatin 
demonstrated decreases in BrdU positive cells within the hippocampus and corresponding 
increases in apoptotic cells 1 day after treatment.  Interestingly, while both BCNU and 
cyclophosphamide are alkylating agents, comparing the results reveals that even though 
each compound reduces proliferation, cyclophosphamide does so without causing 
increases in cell death, while BCNU treatment increase rates of cell death.  The 
discrepancy between these results suggest that underlying mechanisms that lead to 
compromised levels of neurogenesis may differ across chemotherapeutic agents, and may 
be unique to each compound.  Regardless of differences in the exact nature of neurogenic 
disruption, it is clear that chemotherapy agents induce reductions in neurogenic 
proliferation following treatment. 
Lack of Long-Term Data:  Most of the studies that have assayed neurogenesis 
levels in animals treated with chemotherapy compounds have assessed animals within a 
relatively short time following treatment, typically ranging from several days to weeks.    
While it is often claimed that deficits in neurogenic proliferation shortly following 
chemotherapy treatment contribute to the cognitive problems seen shortly after 
chemotherapy administration in animal models, this seems unlikely given the fact that 
newborn neurons take approximately 6 weeks to display similar morphological and 
functional characteristic as fully mature cells within the DG (Song et al., 2012).  It is 
more likely that behavioral deficits detected within a few weeks after treatment relate to 
the sickness and fatigue effects of treatment or reflect toxicity induced cell death within 
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the CNS rather than to any reductions in neurogenic proliferation.  For instance, Yang 
and colleagues (2010) used both Ki-67 and doublecortin (DCX), a protein expressed in 
immature neurons, to assess neurogenesis in mice treated with cyclophosphamide.  They 
detected a sharp decline in both Ki-67 and DCX positive cells during the first 24 hours 
after treatment, but these reductions normalized over the next 10 days, suggesting 
recovery.  Interestingly, concurrent behavioral tests indicated transient deficits that 
corresponded to the neurogenesis data, with animals exhibiting impairment 12 hours post 
injection in both a passive avoidance task and in a novel object recognition task.  When 
these behavioral tasks were reexamined 10 days after treatment no deficits were detected 
(Yang et al., 2010).  While Yang and colleagues (2010) suggest that the cognitive deficits 
detected are potentially due to decreases in neurogenesis, this seems unlikely given the 
time it takes for new neurons to mature and become functionally integrated.  I believe 
these results are the product of sickness related side effects of chemotherapy treatment. 
When examining the handful of studies that have assessed the long-term effects of 
chemotherapy compounds on neurogenesis, all of them argue that their data support the 
idea that chemotherapy compounds can cause long-term alterations in neurogenesis.  
Dietrich et al. (2006) and Han et al. (2008) both present data with statistically significant 
reductions in neurogenic proliferation detected at the longest time point of assessment (42 
days in Dietrich et al., 2006 and 6 months in Han et al., 2008) for at least some of the 
chemotherapy compounds used.  Furthermore, Mondie et al. (2010) found that 
chemotherapy treatment can induce multiple episodes of decreased cellular proliferation 
within the DG that can be detected up to 12 weeks post treatment, but appear to be 
transient.  While these results are promising, they represent the only attempts within the 
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literature to address the long-term aspects of neurogenic proliferation alterations 
following chemotherapy treatment.   
Investigation of long-term changes in neurogenic proliferation following 
chemotherapy treatment is needed to address gaps within the research literature.  Thus, it 
remains to be determined if the effects of chemotherapy on neurogenesis could explain 
long-lasting CRCI within the human literature.  Without further investigation it will be 
difficult to determine to what extent populations of neurogenic cells within the 
hippocampus may be vulnerable to various chemotherapeutic agents and to what degree 
any disruptions detected may persist long-term. 
Timing Profiles of Neurogenesis Reductions Differ by Drug: Although long-
term data regarding decreases in neurogenesis following chemotherapy treatment is 
scarce, there is limited evidence that timing profiles for these decreases may differ across 
chemotherapy compounds.  For instance, Dietrich and colleagues (2006) examined the 
long-term neurogenic proliferation profiles of mice treated with cytarabine, BCNU, or 
cisplatin.  Levels of BrdU labeled cells were assessed in the subventricular zone (SVZ) 
and the dentate gyrus of the hippocampus 1 or 42 days after treatment (cytarabine was 
tracked up to 56 days).  Although mice treated with cytarabine exhibited significant 
decreases in proliferative cells within SVZ immediately following treatment, which was 
also detected 56 days after treatment, significant decreases within the DG were only 
detected on day 56.  A somewhat similar pattern was seen with BCNU administration 
which led to immediate decreases in proliferative cells in the SVZ that were maintained 
at day 42, but decreases detected in the DG never reached statistical significance.  In 
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contrast, cisplatin administration reduced proliferation immediately following treatment 
within both the SVZ and DG, but these reductions were not detected at day 42.   
In a related study conducted by the same group, Han and colleagues (2008) found 
that mice treated with 5-fluorouracil exhibited a different timing profile.  Results 
indicated that mice treated with 5-fluorouracil demonstrated both an immediate short-
term deficit in cell proliferation within the SVZ, followed by a rebound to control levels 
at 7 and 14 days after treatment.  Reductions in proliferation within the DG were detected 
on day 14, followed by a rebound to control levels on day 56.  Interestingly, while 
neurogenesis level was found to return to baseline approximately 2 weeks after treatment 
in the SVZ and at day 56 in the DG, this recovery was transient, as reemergence of these 
deficits occurred with long-lasting suppression of proliferating cells detected in both the 
SVZ and the DG when animals were examined at 6 months post-treatment. 
Finally, Mondie et al. (2010) conducted a study that examined the long-term 
effects of thiotepa on neurogenesis within mice.  Animals were given BrdU 30 minutes 
before tissue collections done at weekly time points throughout the experiment including: 
weeks 0, 1, 2, 3, 4, 6, 12, and 30 following chemotherapy treatment.  Result indicated an 
initial 50% decrease in BrdU positive cells within the DG immediately after treatment.  
This decrease was followed by a recovery in proliferation levels over the next three 
weeks.  However, significant decreases remerged when examined on weeks 4, 6 and 12 
post-chemotherapy treatment.  In addition to these proliferative assays, Mondie et al. 
(2010) found that when animals received BrdU at the completion of chemotherapy 
treatment, and were assessed over the following 4 weeks, no labeled BrdU positive cells 
were detected past week 0.  This suggests thiotepa may be capable of inducing decreases 
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in neuronal proliferation up to 12 weeks after treatment and drastically inhibits the 
survival of cells born during and immediately following chemotherapy treatment.  
Mondie et al. (2010) argues that natural age related reductions in neurogenesis may be 
responsible for a floor effect at 30 weeks making it difficult to detect any reductions in 
neurogenic proliferation due to chemotherapy treatment.  Interestingly, this pattern of 
results may represent an accelerated aging effect, with chemotherapy treated animals 
demonstrating early, age-like reductions in neurogenesis that occur before control 
animals.  Like other chemotherapy agents, these disruptions within the DG may represent 
a unique long-term profile. 
Thus, chemotherapeutic agents can cause significant decreases in proliferation 
levels, and negatively impact the survivability and integration of newborn cells in the 
CNS.  The literature discussed above suggest that chemotherapy drugs may not only 
cause decreases in hippocampal cellular proliferation, but that each chemotherapy 
compound may have a unique timing profile during which these induced alterations in 
neurogenesis occur.  These unique profiles provide further support that subtle differences 
present within the current neurogenesis CRCI animal literature may be related to different 
underlying physiological mechanisms.  Further research is required to understand to what 
degree each chemotherapy compound may disrupt neurogenesis over time in order to 
understand how these proliferative changes relate to and may be responsible for CRCI.  
Human imaging research has suggested that structural and functional changes within the 
brain occur at two distinct time periods, one early (months to 1-2 years) and another later 
(3 years or more) following chemotherapy treatment (McDonald et al., 2012; Kesler et 
al., 2009).  It is unclear to what degree these detected difference may be caused by 
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chemotherapy induced neurogenic disruption.  Identifying which chemotherapy 
compounds can produce long-term suppression of neurogenesis and the time course of 
these effects is essential.  This information will elucidate to what degree neurogenesis 
mechanisms may relate to structural and functional changes detected within the brain 
following chemotherapy treatment. 
Theoretical Impact of Neurogenesis on Cognition: Unfortunately, while there is 
evidence that various stages of neurogenesis can be negatively affected by a variety of 
chemotherapy compounds, the link between neurogenesis and its role in learning and 
memory is not well understood.  The lack of clarity regarding the extent to which adult 
neurogenesis may contribute to learning and memory function makes it difficult to 
evaluate cognitively within CRCI models.  However a variety of supported theories exist 
suggesting different ways in which hippocampal neurogenesis may be involved with 
learning and memory including: pattern separation, temporal encoding, and memory 
resolution (Aimone et al., 2014). 
Briefly, pattern separation refers to the ability of neurons or networks of neurons 
to respond differently to different, yet very similar possible cortical input. Theoretically 
this ability would allow for the optimal formation of distinct memories even when events 
and information share a high degree of similarity.  The large number and high density of 
the neurons within the dentate gyrus, relative to other medial temporal structures, make it 
uniquely suited for continual processing and storing information distinctly (Aimone et al., 
2014).  
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According to theories regarding temporal encoding, ongoing proliferation of 
neurons within the dentate gyrus allows cortical networks within the structure to allocate 
different populations of newborn cells to different episodic events (Aimone et al., 2014).  
Depending on temporal proximity of experienced events, information will either be 
encoded by the same or different populations of young neurons.  Thus, events that occur 
in close temporal proximity are related in long-term episodic memory while those events 
that occur later are encoded by a new set of cells.  It is theorized that this process 
enhances the effectiveness of temporal separation for memory of events far apart in time 
and increases temporal integration for events that occur around the same time. 
Theories regarding the role of the dentate gyrus and neurogenesis in memory 
resolution incorporate aspects of both pattern separation and temporal encoding. 
Physiological properties of dentate gyrus cells change as they mature, allowing more 
broadly tuned immature neurons to assist with pattern integration and more mature 
neurons to be tightly tuned and assist with pattern separation (Deng et al., 2010).  As the 
dentate gyrus continually produces new sets of neurons, there is a constant supply of both 
young and newly matured cells that allow for a combination of sparse and distributed 
coding systems to act simultaneously.  It is theorized that this feature allows the dentate 
gyrus to assist in high resolution memory formation, encoding detailed memory 
representations that link experiential information for what, where and when (Aimone et 
al., 2014).  Interestingly, Frankland et al. (2013) suggests the same proprieties that may 
make the dentate gyrus important for memory resolution may make it important for 
processes involved with forgetting.  Continuous neurogenesis within the dentate gyrus 
may represents a decay process that works to persistently degrade and clear memories 
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from the hippocampus further ensuring that pattern separation within memory traces is 
achieved.  
Unfortunately the behavioral evidence regarding these various theories is complex 
and widely debated, making it difficult to provide a definitive answer regarding the role 
of hippocampal neurogenesis in learning and memory.  Even if a clear link between 
hippocampal neurogenesis and learning and memory can be established, it does not 
necessarily mean that the cognitive deficits observed after chemotherapy treatment are 
caused by deficits in hippocampal neurogenesis.  In fact, Evenden et al. (2013) suggests 
that focus on neurogenesis and hippocampal based tasks within the animal literature has 
begun to create a divergent rift between animal researchers and the human literature, 
where studies tend to emphasize frontal cortical deficits involving working memory in 
which neurogenesis has traditionally been viewed to have little suggested influence. 
It is important to note, however, that there is evidence to suggest that while 
working memory and long-term memory systems are independent, when tasks 
traditionally thought of as short-term memory start to exceed working memory capacity 
or when rehearsal mechanism are inhibited, medial temporal lobe structures may be 
recruited (Shrager et al., 2008).  This suggests that in situations in which there is an 
abundance of complex stimuli presented simultaneously, medial temporal lobe structures 
including the hippocampus may assist in memory processing and maintenance over short 
time intervals.  If chemotherapy treatment has compromised the function of these systems 
by interfering with neurogenesis, it may lead to a failure of long-term memory systems in 
these "working memory" like situations.   
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When viewed as a whole, the literature concerning the impact of neurogenesis on 
cognition suggests that these new cells are likely important, especially in cognitively 
demanding situations.  While these continually renewing neurons within the DG have 
been shown to be related to traditional hippocampal functions, the potentially complex 
role these cells play in cognition is still unclear.  Given this nuanced role, it makes sense 
to confirm the cellular impact of chemotherapy compounds on neurogenic zones within 
the DG before attempting to quantify cognitive deficits that my result from these insults.  
Furthermore, establishing long-term temporal profiles of potential neurogenesis related 
decreases following chemotherapy treatment in animal models will provide critical 
evidence either supporting the theory that CRCI is associated with disrupted adult 
neurogenesis or that it is unlikely to be an important factor in cognitive declines detected 
in patient populations. 
Potential Cellular Mechanisms 
Neuroinflammation:  One possible mechanism by which chemotherapeutic agents may 
induce cognitive deficits and damage throughout the CNS is through neuroinflammation.  
Inflammation begins as a defense mechanism initiated in part by microglial cells, which 
are considered to be the primary resident immune system cells of the CNS.  Microglia 
actively monitor their external environment, and act quickly upon the detection of an 
insult to neutralize it and restore normal structure and function.  Acute inflammation of 
nervous tissue is characterized by rapid activation of microglia, during which these cells 
quickly alter their genetic expression and morphology, and initiate and mediate the 
inflammatory response (Garden, 2013).  This response includes the release of a variety of 
pro-inflammatory cytokines that include, but are not limited to: tumor necrosis factor 
 49 
alpha (TNFα), Interlukin-1 (IL-1), and Interlukin-6 (IL-6).  These cytokines act as 
chemical messengers that both trigger and organize the inflammatory response by 
recruiting other cells and pro-inflammatory processes to the site of damage.  Typically 
these responses are tightly regulated, but if microglia remain chronically active, this can 
result in a self propagating and deleterious process marked by chronic inflammation and 
cytokine dysregulation within the CNS (Block & Hong, 2005; Ahles et al., 2007).  
Dysregulation of cytokine release can promote oxidative stress leading to an escalating 
cycle of damage with greater levels of neuroinflammation leading to higher levels of 
oxidative stress and vice versa (Wilson et al., 2002).  Chemotherapy agents can cause 
cytokine release in the periphery that may subsequently induce inflammation, cytokine 
release and activation of microglia within the CNS, even in the absence of direct contact 
between chemotherapy agents and the CNS.  Sentinel cells in the periphery such as 
macrophages, monocytes, dendritic cells, and Kupffer cells are sensitive to toxic 
substances and respond to potentially harmful agents by releasing pro-inflammatory 
cytokines (Wood et al., 2006).  Significant communication between cytokines within and 
outside the CNS exists via transport across the blood brain barrier or through the vagus 
nerve (Ahles et al., 2007).  The release of pro-inflammatory cytokines like IL-1β and 
TNFα rapidly respond and peak following an immune challenge, and are thought to 
support the mobilization of the immune response initiating a cascade of cytokine 
signaling.  If these pro-inflammatory cytokines are transported across the BBB they can 
then quickly activate microglia within the CNS to mount an immune response.  Another 
cytokine, IL-6, is an inflammatory-responsive cytokine that has both pro-inflammatory 
and anti-inflammatory properties (Wood et al., 2006).  IL-6 production is triggered by 
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release of IL-1β and TNF-α, but subsequently down-regulates the activity of IL-1β and 
TNF-α once it accumulates causing an attenuation of the inflammatory response.  Unlike 
IL-1β and TNF-α that peak rapidly, IL-6 peaks gradually, and can remain elevated for 
several hours following its release.  IL-6 is particularly important within the CNS where 
it is thought to play a role at the hypothalamus, triggering increases in body temperature, 
and like other cytokines, may interact with P38 mitogen-activated protein kinase (p38-
MAPK).  This protein is thought to be responsive to environmental stressors, to induce 
fatigue and sickness-like behavior, alter cell differentiation, and induce apoptosis. 
Wood et al. (2006) examined the ability of the chemotherapeutic agent etoposide 
to induce pro-inflammatory cytokine release in blood of mice.  Results suggest that in 
addition to reduced voluntary wheel-running activity, mice exposed to etoposide showed 
significant increases in the level of IL-6 found in blood collected outside the CNS (Wood 
et al., 2006).  In addition, follow-up in vitro application of etoposide to murine 
macrophages caused an increase in IL-6 gene expression, IL-6 protein release and 
activation of p38-MAPK within cultured media (Wood et al., 2006).  Interestingly, pre-
treatment of macrophages with the p38-MAPK inhibitor ML3403, completely blocked 
both p38-MAPK activation and increases in IL-6, suggesting that IL-6 cytokine 
production may be dependent on p38-MAPK activation.  Other studies have suggested 
that increased p38-MAPK activity is required for some chemotherapeutic agents to 
induce cytotoxicity.  For instance, Elsea et al. (2008) found that p38-MAPK blockade 
selectively diminished cytotoxicity associated with administration of etoposide, 5-
fluorouracil, and doxorubicin, but not docetaxel, in murine macrophages.   
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Christie et al. (2012) demonstrated that while either cyclophosphamide or 
doxorubicin could induce behavioral deficits seen with rats assessed in both novel object 
recognition and contextual fear conditioning tasks, only animals treated with 
cyclophosphamide had increased levels of activated microglia (ED1-positive cells) 
throughout the hippocampus.  This suggests that cyclophosphamide may induce 
behavioral deficits through microglia mediated neuroinflammatory mechanisms while 
doxorubicin may either not rely on an inflammatory mechanism or do so without overtly 
activating microglia.  Furthermore, Borniger et al. (2017) found that the timing of 
changes in the expression of pro-inflammatory genes in mice administered a combination 
of cyclophosphamide and doxorubicin varied by tissue type.  This suggests that 
inflammatory mechanisms activated following chemotherapy exposure may be under 
circadian influence and more toxic to certain tissues at particular circadian intervals. 
In a related study, Briones and Woods (2014) examined the effects of 
cyclooxygenase (COX-2) inhibitor, NS-393, to block the inflammatory response in 
female rats treated with a combination of cyclophosphamide, methotrexate, and 5-
fluorouracil given weekly for 4 weeks.  COX-2 is a key enzyme responsible for the 
synthesis of prostaglandin E2, a ubiquitous central pro-inflammatory mediator.  
Injections of 10 mg/kg NS-393 were given to animals 1 hour after receiving the first 
chemotherapy treatment followed by daily injections for 28 days.  Results indicated that 
rats treated with chemotherapy had elevated levels of pro-inflammatory cytokine IL-1β, 
TNFα, and COX-2.  These differences persisted for 4 weeks after treatment.  Rats treated 
simultaneously with the COX-2 inhibitor NS-393 showed attenuated chemotherapy 
induced neuroinflammation.  Behavioral results from the same study show a similar 
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pattern of results with chemotherapy treated animals demonstrating impairment on two 
variants of the Y maze tests, one using temporal discrimination and the other using object 
placement, compared to saline controls and rats treated with NS-393 and chemotherapy.  
Together these studies suggest that chemotherapy compounds can induce increases in 
pro-inflammatory cytokines and microglia activity that persist up to 1 month after 
treatment.  This neuroinflammation may be related to detected cognitive impairments. 
Recent research suggests that neuroinflammation associated with chemotherapy 
treatment may induce both hippocampal and cortical deficits that are associated with both 
behavioral impairment and compromised neuronal architecture (e.g., reduced dendritic 
arborization and decrease spinogenesis) (Acharya et al., 2015).  Acharya and colleagues 
further found that intrahippocampal transplantation of human neural stem cells can 
resolve both cognitive impairments, and cellular insult associated with chemotherapy 
treatment.  The study found rats treated with cyclophosphamide produced behavioral 
deficits on a variety of object recognition tasks when tests were conducted between 5-7 
weeks after completion of treatment.  Tissue analysis revealed an approximate 2 fold 
increase in the number of activated microglia, indicated using a CD68 antibody marker, 
in the DG, CA1 and CA3 regions of the hippocampus.  This neuroinflammation was not 
detected in saline treated controls, and was suppressed in animals grafted with human 
neural stem cells after completion of chemotherapy treatment.  Significant decreases in 
neuronal architecture and ultrastructure measures in chemotherapy treated animals 
relative to controls were detected and included: dendritic complexity, total dendritic 
length, total dendritic volume, and spine density of neurons within the DG, CA1 and CA3 
regions of the hippocampus.  Chemotherapy induced decreases in all of these measures 
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were not detected in animals that received stem cell transplantation following 
chemotherapy; the authors suggest that the capability of grafted stem cells to protect 
animals from neurocognitive chemotherapy related insult may depend on the ability of 
grafted stem cells to attenuate activation of microglia, suppress cytokine signaling, and 
reduce neuroinflammation within the hippocampus (Acharya et al., 2015). 
While neuroinflammation has become one of the more popular candidates of 
mechanisms leading to CRCI, there have been some inconsistencies within the literature 
regarding the ability of chemotherapeutic agents to induce neuroinflammation.  For 
example, Seigers et al. (2010) examined the effects of methotrexate on 
neuroinflammation in rats.  Results indicated that while microglia activation as measured 
by cell morphology was elevated in the hippocampus 3 weeks after administration, 
multiplex analysis of various cytokine levels within hippocampal tissue, assayed 5 days 
and 20 days after treatment, revealed no significant differences compared to controls.  
While it is not yet clear exactly how neuroinflammation may be linked to CRCI, it 
certainly represents a plausible mechanism by which proliferative cell populations and 
white matter tracts within the CNS may be damaged. 
Oxidative Stress:  Oxidative stress results from an imbalance between systemic creation 
of reactive oxygen species (ROS) and both endogenous and exogenous compounds and 
systems that detoxify and repair oxidative damage.  Reactive oxygen species (ROS) are a 
natural byproduct of the normal metabolism of oxygen, in which they are mainly 
produced within the respiratory chain of mitochondria (Wang et al., 2006).  If an 
imbalance between antioxidant mechanisms and ROS generation is created, elevated 
levels of ROSs can lead to mutations in mitochondrial DNA.  These mutations can lead to 
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a cycle where mitochondrial DNA coded proteins have more errors, causing altered 
electron transfer.  This can eventually lead to more ROS generation (Seigers et al. 2011).  
If the pace of ROS generation surpasses the body‘s ability to detoxify them, significant 
cell damage can occur including: DNA damage, lipid peroxidation, damage to proteins, 
and inactivation of certain enzymes.  In particular, oxidative stress has been suggested to 
be one of the most common causes of DNA damage within neurons (Ahles et al., 2007).  
DNA damage within cells including neurons can lead to apoptosis.  
Since most chemotherapeutic agents are designed to disrupt DNA, many believe 
that mitochondrial DNA may be a potential target of chemotherapy treatment induced 
ROS formation and contribute to increased levels of oxidative stress.  According to Ahles 
et al. (2007), treatment with chemotherapeutic agents is associated with both increased 
levels of free radicals (not involving oxygen) and reduced antioxidant capacity.  Both can 
contribute to increased oxidative stress and subsequent DNA damage.  Cells within the 
CNS, including both neurons and oligodendrocytes may be particularly vulnerable to 
increased levels of oxidative stress as the brain consumes large amounts of energy and 
oxygen. 
Potential Neuroprotectants 
Understanding the neurological dysfunction and cellular mechanisms that underlie 
CRCI are current goals within the research literature.  While basic research continues to 
be important, current research emphasis is also interested in translational efforts 
understanding and impacting patient‘s clinical outcome.  Preventing and repairing 
damage caused by chemotherapy treatment has become a priority.  As such, research into 
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compounds that can act as neuroprotectants throughout the duration, or potentially even 
after a course chemotherapy treatment, have become more common.  The exact processes 
involved in CRCI have yet to be determined, but a variety of compounds have been 
suggested to be beneficial in reducing the negative effects associated with chemotherapy 
treatment.  The following neuroprotectants may be effective in preventing or repairing 
damage caused by chemotherapy treatment and their efficacy or lack thereof may be 
informative when elucidating cellular mechanism underlying chemotherapy related 
damage.  
Antidepressants:  It is well established that long-term antidepressant treatment can up-
regulate expression of brain BDNF and cAMP response element binding protein (CREB), 
inducing changes in both synaptic plasticity and neuronal adaptation (Nibuya et al., 1996; 
Thome et al., 2000).  A variety of antidepressant treatments including: serotonin selective 
reuptake inhibitors (SSRI), norepinephrine selective reuptake inhibitors, monoamine 
oxidase inhibitors and induced electroconvulsive seizures are known to increases levels 
of neurogenesis within the adult hippocampus (Dranovsky & Hen, 2006; Duman et al., 
2000, 2001; Malberg et al., 2000).  In a study conducted by Wang et al. (2008), mice 
treated chronically with fluoxetine (an SSRI) for 28 days showed not only increases in 
hippocampal proliferation but increased rates of neuronal maturation and dendritic 
arborization following treatment.  Wang et al. (2008) also examined the effects of chronic 
fluoxetine on the novelty-suppressed feeding test, which is a behavioral task that 
measures latency to begin eating as an index of antidepressant/anxiety-like behavior.  
Results revealed beneficial effects of chronic fluoxetine exposure that could be reversed 
with ablation of neurogenesis with x-irradiation.   Results from several other studies 
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indicate that while chronic stress down-regulates genes important for proliferation and 
plasticity within the hippocampus, treatment with antidepressants can reverse these 
changes in gene expression suggesting a common mechanism (Alfonso et al., 2004; 
Dranovsky & Hen, 2006; Mahar et al., 2014).  While the neurogenesis boosting effects of 
fluoxetine have been detected following at least 1 week of treatment, most reports 
indicate the strongest effects of fluoxetine on neurogenesis after 3-4 weeks of treatment 
(Malberg et al., 2000; Miller et al., 2008).  Interestingly, the temporal delay 
(approximately a month) in the efficacy of antidepressants in the treatment of depression 
in humans and animal models of chronic stress seems to match the time course required 
for proliferating neurons to become functionally integrated (Ge et al.2007; Jacobs et al., 
2000; Mahar et al., 2014).  These converging lines of experimental evidence suggest that 
antidepressants alter and promote proliferative cell populations within the hippocampus. 
 The effect of antidepressants on proliferating cells is not limited to neurons within 
the hippocampus.  In a study conducted by Czéh et al. (2007), chronic fluoxetine 
treatment was associated with an increased number of BrdU positive cells indicative of 
cellular proliferation in both the dentate gyrus of the hippocampus and the medial 
prefrontal cortex (mPFC).  In addition to BrdU, phenotypic analysis was done using 
double immunofluorescence labeling with NeuN (a neuronal marker) or NG2 (a glial 
marker).  Results indicated that a majority (70-77%) of BrdU positive cell within the DG 
expressed NeuN, while the majority (63-80%) of BrdU positive cell within the mPFC 
expressed NG2.  These results suggest that chronic fluoxetine treatment can boost levels 
of both neurogenesis and gliogenesis.  Interestingly, the detrimental effects of chronic 
social stress on both proliferation and survival of new neurons in the hippocampus and 
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new glial cells in the mPFC were reversed after 4 weeks of fluoxetine treatment.  This 
study illustrates that fluoxetine not only boosts neurogenesis, but can boost gliogenesis as 
well. 
 There is evidence that antidepressants may have neuroprotectant properties within 
animal models of chemotherapy related cognitive impairment.  For instance, ELbeltagy 
and colleagues (2010) found that rats treated with 5-fluorouracil (5-FU) injections over 
two weeks exhibited impaired performance on a novel location recognition task (1 day 
after treatment) and had fewer Ki-67 positive cells in the dentate gyrus compared to 
controls (3 days after treatment).  In contrast, animals that received 5-FU while also 
receiving a dose of 10 mg/kg/day fluoxetine via drinking water over three weeks, showed 
no significant impairment on the novel location task and no significant decrease in 
neurogenesis compared to controls.   
 Similar results were detected by Lyons et al. (2011).  They found a beneficial 
effect of 10 mg/kg/day fluoxetine pre-treatment in rats treated with methotrexate.  While 
animals treated with methotrexate in the absence of fluoxetine showed impaired 
performance on a novel location recognition task and exhibited decreases in both cell 
survival and proliferation within the dentate gyrus when examined at approximately a 
week following treatment.  Animals that received fluoxetine were protected from 
chemotherapy insult in both behavioral and cellular measures.  These studies suggest that 
antidepressants may be an effective neuroprotectant which may prevent short-term 
decreases in neurogenesis associated with chemotherapy treatment.  The timing and long-
term capacity of antidepressants to produce and maintain these beneficial neurogenesis 
related effects remains unknown and represent an opportunity for further research. 
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Antioxidants:  The generation of reactive oxygen species is a natural byproduct of 
normal respiration, but if left uncontrolled these reactive molecules can cause damage to 
cells within the CNS by damaging proteins, lipids, mitochondria, and DNA.  It is thought 
that during periods of oxidative stress, and progressively over time, ROSs may build up 
and overwhelm homeostatic endogenous antioxidant defenses within the CNS, causing 
damage to both neurons and glial cells (Andersen, 2004; Dröge & Schipper, 2007).  The 
‗free-radical theory of aging‘ (Harman, 1992) hypothesizes that the aging brain and body 
are susceptible to increasing levels of oxidative stress and that antioxidant 
supplementation may increase both lifespan and lead to better functional outcomes.  
While the details regarding the exact role oxidative stress may play in aging is still 
debated, it is fairly well established that antioxidants can have positive effects on the 
cognitive outcomes associated with age and age-related diseases.  In a cross-sectional, 
prospective study of dementia, Zandi et al. (2004) found that antioxidant and vitamin 
supplements were associated with reduced prevalence and incidence of Alzheimer 
disease (AD) in their sample of 4740 elderly (65 years or older) residents of Cache 
county, Utah.  Krikorian et al. (2010) found similar results when they evaluated the 
effects of consuming concord grape juice, known to contain high levels of antioxidants, 
in older adults for 12 weeks.  Results from the California Verbal Learning Test indicated 
that individuals that had consumed grape juice had significantly higher rates of item 
acquisition compared to those consuming the placebo, indicative of better verbal 
memory.  Similar results have also been reported in animal models where the effects of 
foods rich in antioxidants such as blueberries (Joseph et al.1999), strawberries (Joseph et 
al.1998), concord grapes (Shukitt-Hale et al., 2006), and red wine (Anekonda, 2006) have 
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been shown to have both preventative and restorative effects on age-related cognitive and 
motor dysfunction.  Together these studies suggest that antioxidant supplementation may 
be a useful tool in combating oxidative stress mechanisms that lead to cognitive 
impairments. 
Melatonin:  Melatonin is an endogenously produce indoleamine that is known to play a 
significant role in circadian rhythms and synchronicity (Kennaway & Wright, 2002; 
Reiter, 1993).  Melatonin and its metabolites are direct free radical scavengers (Reiter, 
2000; Tan et al., 2002; Hardeland, 2005), known to stimulate antioxidative enzymes 
(Rodriguez et al., 2004;  Barlow-Waldon et al. 1995), chelate transition metals which 
normally participate in redox reactions (Limson et al., 1998) and reduce free radical 
formation (Hardeldand et al., 2005; Leon et al. 2004; López et al., 2009).  Melatonin is 
able to enter both lipid and aqueous environments, unlike other antioxidants such as 
vitamins C and E, which allow for increased free radical scavenger efficiency (Reiter et 
al., 2009).  Melatonin is also known to reduce toxicity, ototoxicity and tinnitus due to the 
use of aminoglycosides and cisplatin without causing attenuation of functional efficiency 
of either drug (for review see Reiter et al., 2011).  Melatonin has also been demonstrated 
to promote survival and dendritic maturation in adult neurogenesis (Ramirez-Rodriguze 
et al., 2011), to effectively protect developing oligodendrocytes following white matter 
damage in neonatal rats (Olivier et al., 2009; Villapol et al., 2011), and can reduce glia-
mediated inflammatory responses (Wu et al., 2011).  Together these properties make 
melatonin an ideal neuroprotectant compound capable of supporting a wide range of 
positive reparative and protective responses to CNS insult.   
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The primary goals of research efforts regarding chemo-brain are to identify the 
source of CRCI and ultimately to minimize and possibly reverse these negative side 
effects.  Each of the neuroprotectants discussed above provide a possible method for 
protecting against damage caused by chemotherapy treatment.  Furthermore, it is possible 
that these compounds may even assist cellular repair mechanisms following 
chemotherapy insult, accelerating recovery, and lead to better clinical outcomes for 
cancer survivors.  By investigating the effects of these neuroprotectant compounds on 
cognitive and cellular models of CRCI, research based achievements can begin to 
translate into clinical applications. 
Current Study Justification  
Summarizing the research literature discussed, there is clear evidence that a 
variety of chemotherapeutic compounds negatively impact proliferative cell populations 
within the CNS.  In addition, limited data suggests that white matter tracts may also be 
vulnerable to chemotherapy treatment.  While several studies suggest that chemotherapy 
compounds are toxic to cells within the CNS and disrupt neurogenic processes within the 
hippocampus following treatment, the mechanisms and time course of these processes are 
not well understood.  Most of the studies conducted to date have focused on the effects of 
chemotherapy within the CNS during and shortly after treatment.  Only 3 studies have 
examined the long-term effects (greater than 1 month post-treatment) of chemotherapy on 
hippocampal proliferation (Dietrich et al., 2006; Han et al., 2008; Mondie et al., 2010).   
Given that laboratory mice typically have an average life-span of 600 days 
(Festing, 1998), deficits detected 30 days post chemotherapy treatment should not be 
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considered long-term or permanent without subsequent extended testing.  Thus, the bulk 
of the current animal literature, in which decreases in neurogenesis have been detected 
shortly after treatment, is unable to elucidate reports of long-term cognitive decline in 
patients that are detected up to 10 years after treatment (Raffa & Tallarida, 2010). 
The current study attempts to expand upon knowledge within the current literature 
regarding the time course of CRCI.  By evaluating both immediate and delayed effects of 
chemotherapy treatment on proliferative processes within the CNS, the current study may 
elucidate to what degree disrupted hippocampal neurogenesis may account for CRCI 
detected in patient populations.  The long-term nature of this study provides a better 
understanding of the initial deficits, any recovery periods, and possible persistent 
problems in neurogenesis capacity that may appear following chemotherapy treatment.  
Finally, the current study attempted to evaluated the effectiveness and establish 
long-term profiles of two different neuroprotectants: the antidepressant fluoxetine and the 
neurohormone melatonin.  Evaluating the effectiveness of each of these compounds to 
prevent and possibly restore normal structure and function within the CNS following 
chemotherapy treatment expands the understanding of potential clinical interventions. 
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METHODS AND RESULTS 
Experiment 1 
Aim of Experiment 1 
Several studies have indicated that chemotherapy compounds can negatively 
impact processes involved in neurogenesis and inhibit proliferating cells within the 
hippocampus a few weeks following treatment (Dietrich et al., 2006; Han et al., 2008; 
Mustafa et al., 2008; Seigers et al., 2008; 2009; Janelsins et al., 2010; Mondie et al., 
2010; Yang et al., 2010; Briones et al., 2011; Lyons et al., 2011; Christie et al., 2012; 
Yang et al., 2012).  It is unclear however, whether or not these effects persist at later time 
points and to what degree administration of different classes of chemotherapeutics differ 
in their long-term capacity to impact neurogenesis.   
Results obtained by Janelsins et al. (2010) and Chrisite et al. (2012) have 
indicated that both cyclophosphamide and doxorubicin administration can disrupt 
neurogenesis shortly after treatment (2 days to 4 weeks).  However, it is currently 
unknown whether these effects represent long-term, persistent decreases in neurogenic 
potential and to what degree these two chemotherapy agents may produce unique timing 
profiles with regard to decreases in neurogenic proliferation.  To evaluate the potential 
long-term effects and establish long-term timing profiles for these compounds, the 
present study examined neurogenesis 1 day, 56 days, and 6 months after treatment to 
monitor for long-term changes in proliferation rates similar to those detected with BCNU, 
cisplatin, 5-FU and thiotepa (Dietrich et al., 2006; Han et al., 2008; Mondie et al., 2010). 
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The long-term design chosen for this experiment allowed for assessment of 
neurogenesis utilizing the endogenous proliferative marker Ki-67.  Comparisons of 
potential early and late effects of chemotherapy treatment on cellular proliferation within 
the DG of the hippocampus were assessed.  Given that Dietrich et al. (2006) has already 
demonstrated that chemotherapy compounds can vary with regard to their capacity to 
disrupt neurogenesis over time, the goal of Experiment 1 was to determine the degree to 
which cyclophosphamide and doxorubicin may affect neurogenesis rates and the timing 
profiles of these effects. 
Materials and Methods Experiment 1: 
Subjects:  62 C57BL/6J male 10-11 week old mice were used for the study.  Mice arrived 
from Jackson labs and were acclimated to our animal colony for approximately 2 weeks 
before treatment began.  Animals were housed socially (3-4 mice per cage) in a 
temperature (~70
°
F) and light/dark controlled (7:00am – 7:00pm) environment with food 
and water ad libitium.  Animals were randomly assigned and counterbalanced for initial 
weight across 3 treatment conditions: saline controls, cyclophosphamide, or doxorubicin. 
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Figure 1: Time-line for Experiment 1 
 
 
 
Figure 1:  Animals received injections on days 1, 4, and 7 with saline (0.9% NaCl). 
cyclophosphamide (120mg/kg) or doxorubicin (5mg/kg).  Animals were perfused 1 day, 
56 days or 6 Months after the last injection. 
 
 
Chemotherapy Treatment:  Mice in each group received intraperitoneal (i.p.) injections 
over a period of 7 days (time-line shown in Figure 1).  Cyclophosphamide (120mg/kg 
diluted in 0.9% saline; Acros Organics), doxorubicin (5mg/kg diluted in 0.9% saline; 
Fisher Scientific), or saline (0.9% NaCl) injections were administered on days 1, 4, and 7, 
for a total of 3 injections per animal, as detailed in Janelsins et al. (2010).  However, the 
injection dose used for cyclophosphamide in this study is higher than the 50mg/kg dose 
used in Janelsins et al. (2010).  This higher dose was used in an attempt to maximize any 
long-term neurobiological effects that might be detected.  Because toxicity and tolerance 
to chemotherapeutic compounds can vary drastically as a function of circadian rhythm 
(Focan, 1995), all mice were treated at approximately the same time, 8-9 hours after light 
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onset.  Weight was monitored daily for approximately 4 weeks, then every other day until 
56 days post-treatment.  Thereafter, mice were weighed weekly.  In addition to weight, 
teeth were monitored regularly and trimmed when necessary in order to prevent 
overgrowth which can lead to weight loss. 
Tissue Collection:  Animals were sacrificed and transcardially perfused with 0.9% saline 
followed by 4% paraformeldehyde (PFA) at 1 day (6 saline controls, 6 
cyclophosphamide, and 6 doxorubicin), 56 days (6 saline controls, 6 cyclophosphamide, 
and 3 doxorubicin) and 6 months (7 saline controls, 7 cyclophosphamide, and 4 
doxorubicin) following the last chemotherapy injection.  Brains were extracted and 
submerged in PFA.  Brains were then moved to a 30% sucrose solution and allowed to 
sink prior to being flash frozen.  Six, approximately identical series of 40 µm coronal 
sections were cut into a 0.05% potassium phosphate buffered saline solution (KPBS), 
moved to an antifreeze cryoprotectant, and stored at -20°F until they were needed for 
immunohistochemistry. 
Immunohistochemical Staining:  An aviden/biotin-based peroxidase Vectastain Elite 
ABC Kit (Rabbit IgG) system (Vector Laboratories, Inc.) was used to perform high 
sensitivity, low background immunohistochemical staining on prepared tissue.  For 
detection of Ki-67 proteins, Ki-67 rabbit primary antibodies (Wako Pure Chemical 
Industries, Ltd.) were used in conjunction with the Elite ABC kit.  A titration series was 
conducted to determine the optimal Ki-67 antibody concentration to use with our 
prepared tissue samples in accordance with the recommended immunohistochemical 
staining method suggested by Hoffman et al. (2008).  For Ki-67 immunohistochemical 
staining, a single series of tissue for each animal was selected that encompassed the entire 
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hippocampus (10 sections of tissue for each animal) for staining.  After the tissue was 
selected, it was initially rinsed in 0.05% KPBS 6 times for 10 minutes each to wash the 
cryogenically preserved tissue after which the tissue was incubated in a 1% hydrogen 
peroxide 0.05% KPBS solution for 15 minutes.  Following this incubation, the tissue was 
rinsed again in 0.05% KPBS 4 times for 5 minutes each, and then incubated in a 
(1:4,000) Ki-67 rabbit primary antibody diluted in 0.05% KPBS/0.4% Triton X-100 
solution for 1 hour at room temperature.  The tissue was then stored in the refrigerator at 
approximately 35°F for 48 hours.  Following this incubation period, the tissue was 
thoroughly rinsed in 0.05% KPBS 10 times for 6 minutes each, and then incubated in a 
(1:500) biotinylated, affinity-purified anti-immunoglobulin secondary antibody (Vector 
Laboratories, Inc.) diluted in 0.05% KPBS/0.4% Triton X-100 solution at room 
temperature for 1 hour.  Following another series of 5, 10 minute rinses in 0.05% KPBS 
the tissue was incubated in an avidin biotinylated enzyme complex (ABC) diluted in 
0.05% KPBS/0.4% Triton X-100 solution at room temperature for 1 hour.  Following this 
incubation, the tissue was rinsed 3 times for 5 minutes each in 0.05% KPBS and then 
rinsed 3 times for 5 minutes each in 0.175% sodium acetate.  The tissue then went 
through incubation in a nickel enhanced DAB chromogen solution (2.5% Ni + 2% DAB) 
for 25 minutes.  After this final incubation, the tissue was rinsed 3 times for 5 minutes 
each in 0.175% sodium acetate to stop the chemical reaction, followed by two final rinses 
in 0.05% KPBS for 10 minutes each.  Stained tissue slices were then floated in .0125% 
KPBS and mounted on microscope slides and air-dried for at least 24 hours.  Dried slides 
were dehydrated using graduated EtOH solutions (70-100%) and cleared with HistoClear 
(National Diagnostics Inc.).  Prepared slides were then coverslipped using HistoMount 
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(National Diagnostics Inc.) and allowed to dry for 24 hours.  Bright-field images were 
taken using a Nikon Eclipse E200 microscope equipped with an Accu-Scope Excelis HD 
camera (See Appendix A for an example of captured tissue images).  
Tissue Analysis: Following standard unbiased stereological estimation protocols as 
outlined in (Noori & Fornal, 2011), the number of Ki-67 positive cells within 10 slices of 
the DG of the hippocampus of each animal were counted by eye under 400X 
magnification by a blind rater.  These counts provided an indication of the number of 
actively proliferating cells at the time of sacrifice. 
Results Experiment 1 
Animal Deaths 
Doxorubicin induced toxicity resulted in several animal deaths prior to assigned 
perfusion dates in Experiment 1: 4 deaths occurred in the day 56 group and 7 deaths 
occurred in the 6 month group (often these animals were euthanized following our animal 
care and use protocol).  No deaths occurred within the day 1 group or in any of the 
animals injected with cyclophosphamide.  Any data collected for animals that died prior 
to perfusion were excluded from all analyses, including weight loss analyses.  (See 
Appendix B for mortality data regarding Experiment 1) 
Neurogenesis Analysis Experiment 1 
Figure 2 shows the average number of Ki-67 positive cells detected in all 10 
tissue slices of the hippocampus for Experiment 1 across all three collection time points 
(day 1, day 56, and 6 months).  As shown in Figure 2, younger animals perfused at day 1 
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had higher rates of cellular proliferation compared to older animals perfused at 6 months 
regardless of treatment condition.  While not statistically significant, this trend is also 
seen when comparing animals perfused at day 1 to those perfused at day 56 and those 
perfused at day 56 to those perfused at 6 months.  A 3 x 3 factorial ANOVA [Treatment 
× Day] indicated that there was a significant main effect of day, (F2, 42 = 5.10; p = .01, ηp
2
 
= .20), with no other significant effects detected.  Post hoc analysis (Tukey HSD) 
indicated that animals perfused at day 1 had significantly more Ki-67 positive cells than 
those animals perfused at 6 months (p < .01).  No other pairwise comparisons were 
significant (p’s >.20).  These results indicate that neither cyclophosphamide nor 
doxorubicin administration lead to any significant differences in proliferation rates within 
the DG compared to saline injected animals.  Given prior evidence that both 
cyclophosphamide and doxorubicin are capable of reducing cellular proliferation within 
the DG of treated animals shortly after treatment, exploratory one-way ANOVA‘s were 
conducted at each time point and confirmed there were no statistically significant 
differences in the number of Ki-67 positive cells across treatment conditions at any time 
point (p‘s > .29). 
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Figure 2:  Experiment 1: Tissue Analysis 
 
 
 
Figure 2:  Mean number of Ki-67 positive cells detected in tissue collections at day 1, day 
56 and 6 month, for animals treated with saline, cyclophosphamide, and doxorubicin.  
Error bars represent ±1 standard error of the mean.  A factorial ANOVA indicated a main 
effect of day, (p = .01) with post-hoc analysis (Tukey HSD) indicating animals perfused 
at day 1 had significantly more Ki-67 positive cells than those animals perfused at 6 
months (p < .01).  No significant treatment effect was detected. 
Weight Data Experiment 1 
Weight Loss Analysis:  Previous data collected within my lab (Fremouw et al., 2012a) 
and others (Janelsins et al., 2010; Seigers et al., 2008) suggests that a variety of 
chemotherapy compounds reliably induce weight loss in rodents during and a few days 
after injections have ceased. Given the lack of any detectable treatment effect on 
neurogenesis, weight loss analysis was conducted to provide evidence that the 
chemotherapy doses and the injection protocol used produced expected toxicity levels.  
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To consistently assess weight loss relative to pre-treatment weight within the experiment, 
two-factor mixed-design ANOVAs were used across the injection protocol (from the day 
following the first injection to the first day following the last injection) for each batch of 
animals.  While longer time intervals could have been used with animals perfused at day 
56 and 6 months, the shorter window allowed for consistency in analysis and mapped on 
to weight loss data in previous studies.  In addition, one way ANOVAs and follow-up 
post hoc analysis with Tukey HSD were run on weight data collected on day 1, following 
the end of the injection protocol, to confirm expected weight differences. 
Weights Day 1:  Figure 3, depicts percent weight (relative to pre-treatment weight) as a 
function of day, starting from the day of the first injection to the day after the last 
injection, for the animals that were perfused on day 1.  As shown in Figure 3, animals 
treated with either cyclophosphamide or doxorubicin lost weight during the 7 day 
injection protocol, while control animals receiving saline gained weight.  A two-factor 
mixed-design ANOVA [Treatment × Day] was conducted to analyze weight differences 
between the treatment groups for the first 7 days of the experiment (starting from the day 
following the first injection to the first day following the last injection).  There was a 
significant main effect of treatment, (F2, 15 = 21.13; p < .0001, ηp
2
 = .74) and a significant 
treatment by day interaction (F4.3, 32.5 = 6.77; p < .001, ηp
2
 = .48), Greenhouse-Geisser 
corrected).  A one-way ANOVA confirmed that weight change differed by the end of the 
injection protocol (F2, 15 = 15.67; p < .0001, ηp
2
 = .68).  Post hoc analysis (Tukey HSD) 
indicated that the saline treated group had lost less weight than cyclophosphamide or 
doxorubicin treated groups (p’s < .001). 
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Figure 3:  Experiment 1: Weight Data - Day 1 
 
 
 
Figure 3:  Mean % body weight (relative to pre-treatment weight) as a function of day for 
animals perfused on day 1.  Mice received IP injections of either saline (0.9% NaCl; n = 
6), cyclophosphamide (120 mg/kg; n = 6), or doxorubicin (5 mg/kg; n = 6), on days 1, 4, 
and 7 (INJ1, INJ2 and INJ3).  Error bars represent ±1 standard error of the mean.  A two-
factor mixed-design ANOVA indicated a significant main effect of treatment (p < .0001), 
and treatment by day interaction (p < .001). 
 
 
Weights Day 56:  Figure 4 depicts percent weight as a function of day, starting from the 
day of the first injection to the day after the last injection for the animals that were 
perfused on day 56.  As shown in Figure 4, animals treated with either cyclophosphamide 
or doxorubicin lost weight during the injection protocol while control animals appear to 
have maintained weight.  A two-factor mixed-design ANOVA [Treatment × Day] was 
conducted to analyze weight differences between the treatment groups for the first 7 days 
of the experiment (starting from the day following the first injection to the first day 
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following the last injection).  There was a significant main effect of treatment, (F2, 12 = 
13.58; p < .001, ηp
2
 = .69), a significant main effect of day, (F2.7, 32.7 = 18.16; p < .0001, 
ηp
2
 = .60, Greenhouse-Geisser corrected), and a significant treatment by day interaction, 
(F5.5, 32.7 = 10.64; p < .0001, ηp
2
 = .64, Greenhouse-Geisser corrected).  Thus, the animals 
perfused at day 56 followed a similar pattern of weight loss to those animals perfused at 
day 1; the saline group maintained or increased weight over the first 7 days of the 
experiment while animals injected with cyclophosphamide or doxorubicin lost weight.  A 
one-way ANOVA confirmed that weight change differed by the end of the injection 
protocol (F2, 12 = 20.05; p = .0001, ηp
2
 = .77).  Post hoc analysis (Tukey HSD) indicated 
that the saline treated group had lost less weight than cyclophosphamide or doxorubicin 
treated groups (p’s < .001). 
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Figure 4:  Experiment 1: Weight Data - Day 56 
 
 
 
Figure 4:  Mean % body weight (relative to pre-treatment weight) as a function of day for 
animals perfused on day 56.  Mice received IP injections of either saline (0.9% NaCl; n = 
6), cyclophosphamide (120 mg/kg; n = 6), or doxorubicin (5 mg/kg; n = 3), on days 1, 4, 
and 7 (INJ1, INJ2 and INJ3). Error bars represent ±1 standard error of the mean.  A two-
factor mixed-design ANOVA for the first 7 days of the experiment, indicated a main 
effect of treatment (p < .001), a main effect of day (p < .0001), and a treatment by day 
interaction (p < .0001). 
 
 Animals perfused on day 56 that were injected with either cyclophosphamide or 
doxorubicin lost weight until approximately 2 days after the last injection, at which point 
the cyclophosphamide injected animals began to regain weight while the doxorubicin 
injected animals‘ weight loss plateaued (see Appendix C for a figure of the extended 
weight loss data). 
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Weights 6 Month:  Figure 5 depicts percent weight as a function of day, starting from the 
day of the first injection to the day after the last injection, for the animals that were 
perfused at 6 months.  A similar pattern of weight change was detected.  A two-factor 
mixed-design ANOVA [Treatment × Day] was conducted to analyze weight change 
between the groups over the first 7 days of the experiment (starting from the day 
following the first injection to the first day following the last injection).  As with the 56 
day animals, both main effects of treatment, (F2, 15 = 25.56; p < .0001, ηp
2
 = .77), and day, 
(F2.7, 40.4 = 9.14; p = .0001, ηp
2
 = .38, Greenhouse-Geisser corrected), were detected.  
There was also a significant treatment by day interaction, (F5.4, 40.4 = 6.87; p < .0001, ηp
2
 = 
.48, Greenhouse-Geisser corrected).  Following a pattern similar to those animals 
perfused on day 1 and 56, the weight of saline injected animals perfused at 6 months 
tended to increase slightly over the first 7 days of the experiment while both the 
cyclophosphamide and doxorubicin injected animals lost weight.  A one-way ANOVA 
confirmed that weight change differed by the end of the injection protocol (F2, 15 = 16.13; 
p = .0001, ηp
2
 = .68).  Post hoc analysis (Tukey HSD) indicated that the saline treated 
group had lost less weight than cyclophosphamide or doxorubicin treated groups (p’s < 
.03). 
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Figure 5:  Experiment 1: Weight Data - 6 Months 
 
 
 
Figure 5:  Mean % body weight (relative to pre-treatment weight) as a function of day for 
animals perfused at 6 months.  Mice received IP injections of either saline (0.9% NaCl; n 
= 7), cyclophosphamide (120 mg/kg; n = 7), or doxorubicin (5 mg/kg; n = 4), on days 1, 
4, and 7 (INJ1, INJ2 and INJ3). Error bars represent ±1 standard error of the mean.  A 
two-factor mixed-design ANOVA for the first 7 days of the experiment indicated a main 
effect of treatment, a main effect of day, and a treatment by day interaction (all p‘s < 
.0001). 
 
 Animals perfused at 6 months followed the same general pattern of weight loss 
after the injection protocol that was detected in animals perfused on day 56.  Animals that 
were injected with either cyclophosphamide or doxorubicin lost weight until 
approximately 2 days after the last injection, at which point, the cyclophosphamide 
injected animals began to regain weight while the doxorubicin injected animals‘ weight 
loss plateaued (see Appendix D for a figure of the extended weight loss data).  The 
weight data, as a whole, suggest the most significant weight loss occurs within the first 
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few days following the last injection of cyclophosphamide or doxorubicin which is 
consistent with previous data collected in my lab (Fremouw, et al., 2012a).    
Discussion Experiment 1 
Treatment with cyclophosphamide or doxorubicin has been shown to reduce 
levels of proliferating cells within the DG of mice immediately following treatment 
(Yang et al. 2010; Janelsins et al., 2010; 1 or 2 days after the last chemotherapy injection 
respectively).  In contrast to these previous studies, the results of the present study found 
no significant treatment effect at any of the assessment time points, including tissue 
collected at 1 day after the last chemotherapy injection.  
As previously discussed, the current research literature suggests that each 
chemotherapeutic compound may have a unique temporal profile regarding the capacity 
to reduce neurogenic proliferation.  For instance, Dietrich et al. (2006) detected deficits in 
neurogenic proliferation within the DG of mice 56 days after cytarabine administration, 
while animals treated with BCNU showed no treatment effects within the DG at this 
same time point.  Given the present study‘s results, cyclophosphamide and doxorubicin 
appear to have no effects on proliferation rates within the DG of mice at any of the time 
intervals examined. 
It is unclear why cyclophosphamide or doxorubicin treatment failed to reduce 
proliferation in tissue collected at day 1.  The high level of variability in Ki-67 positive 
cells detected in tissue collected at day 1 makes comparison between treatment groups 
difficult to interpret and may have obscured any possible treatment effect at this time 
point.  The discrepancies between the current study‘s results and previous studies may 
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suggest that reductions in proliferation rates within the DG shortly following treatment 
with these compounds may not be as consistent or robust to experimental parameters as 
previously thought.  For instance, while many of the experimental parameters in the 
present study were the same as those used by Janelsins et al. 2010, (e.g. mouse strain and 
injection schedule) it appears that subtle differences in a variety of factors including: age 
(9 weeks vs. 13 weeks), dose (50 mg/kg vs. 120 mg/kg cyclophosphamide), and 
assessment timing (2 day vs. 1 day after the last injection), may have contributed to the 
different findings despite the similarities across the studies. 
A recent study conducted by Seigers et al. (2016) provides experimental evidence 
that supports the present study‘s findings.  Seigers et al. (2016) was unable to detect any 
reductions in proliferation within the DG of C57BL/6J mice treated with either a single 
injection of cyclophosphamide (150 mg/kg) or doxorubicin (5 mg/kg), when assessed 
utilizing Ki-67 for neurogenic proliferation at either 3 weeks or 16 weeks following 
treatment. 
In summary, Experiment 1 showed that neither cyclophosphamide nor 
doxorubicin caused a decrease in proliferation rates at any of the three time points within 
the study.  While unexpected, the lack of any deficits detected at day 1 is not completely 
inconsistent with the current literature which highlights the degree to which reported 
neurogenesis deficits may differ across studies.  The results of tissue analysis at the later 
time points suggest that neither cyclophosphamide nor doxorubicin treatment cause a 
significant long-term disruption in proliferation rates within C57BL/6J mice. 
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Experiment 2 
Aim of Experiment 2 
The aim of Experiment 2 was to build upon the results obtained by Han and 
colleagues (2008) who examined the effect of 5-FU administration on neurogenesis in 
mice.  While Han et al. (2008) found decreases in neurogenesis within the SVZ at 1 day, 
7 days, 56 days, and 6 months after 5-FU administration, decreases detected within the 
DG only reached significance at 14 days and 6 months after treatment.  In addition to 
these results, Janelsins et al. (2010) has detected deficits in neurogenesis 2 days after 
treatment with 5-FU.  The current study was designed to replicate these findings by 
examining neurogenesis levels in mice 1 day, 56 days and 6 months following 5-FU 
treatment.  In addition, these same time points were used to evaluate the effectiveness of 
two different neuroprotectant compounds, fluoxetine and melatonin, to prevent, protect, 
and/or repair deficits in neurogenesis following chemotherapy treatment.   
The long-term nature of this study provides a timing profile for decreases in 
neurogenesis following treatment with 5-FU and information regarding the effect of 
either melatonin or fluoxetine to alter levels of neurogenesis when co-administered with 
5-FU.  These neuroprotectans were chosen based on prior research indicating that both 
melatonin (Ramirez-Rodriguze et al., 2011) and fluoxetine can boost neurogenesis levels 
(Duman et al., 2000, 2001; Malberg et al., 2000; Dranovsky & Hen, 2006; Czéh et al. 
2007).  Furthermore, animal models of CRCI have already demonstrated that fluoxetine 
can be used to prevent or restore decreases in neurogenesis following 5-FU (ELBeltagy et 
al., 2010) or methotrexate treatment (Lyons et al., 2011), when neurogenesis is assessed 
within 1-2 weeks after treatment.  In addition, melatonin is a potent antioxidant that has 
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been shown to reduce oxidative stress in addition to its proliferative boosting effects 
(Reiter et al., 2000; Tan et al., 2002; Hardeland, 2005; López et al., 2009).  Given these 
established benefits, the effectiveness of these neuroprotectants to alter the impact of 5-
FU treatment on neurogenesis was examined.  
Materials and Methods Experiment 2: 
Subjects:  83 C57BL/6J male 10-11 week old mice were used for the study.  Mice arrived 
from Jackson labs and were acclimated to our animal colony for approximately 2 weeks 
before treatment began.  Animals are housed socially (3-4 mice per cage) in a 
temperature (~70
°
F) and light/dark controlled (7:00am – 7:00pm) environment with food 
and water ad libitium.  Animals were randomly assigned and counterbalanced for initial 
weight across 4 treatment conditions: saline controls, 5-FU and saline, 5-FU and 
melatonin, or 5-FU and fluoxetine.  Due to the administration of fluoxetine and melatonin 
through drinking water, animals were housed by group, to ensure they were receiving 
only their assigned treatment.  
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Figure 6: Time-line for Experiment 2 
 
 
 
Figure 6:  Access to water pre-treatment with melatonin or fluoxetine began 21 days prior 
to the first injection.  Animals received protectant injections on days 1-5 with saline 
(0.9% NaCl), melatonin (25mg/kg) or fluoxetine (12mg/kg). Animals received additional 
injections on days 1, 3, and 5 with saline (0.9% NaCl) or 5-FU (70mg/kg).  Animals were 
perfused 1 day, 56 days or 6 Months after the last injection. 
 
 
Neuroprotection Water Treatment:  Prior to initial chemotherapy administration, mice 
received neuroprotective treatment administered through the drinking water, as detailed 
in ELBeltagy et al. (2010).  Water administration allows for long-term treatment, 
preemptively boosting neurogenic levels and antioxidant levels in an attempt to prevent 
5-FU induced reductions, without increasing stress levels unnecessarily through repeated 
injections.  Water bottles were covered with aluminum foil to prevent light exposure to 
the melatonin treated water (light-sensitive) and this was controlled across groups.  Water 
was weighed and changed every 4 days in order to calculate water intake and adjust the 
melatonin and fluoxetine concentration accordingly to maintain the target dose.  Water 
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intake was estimated by calculating the difference between average daily evaporation 
levels (calculated from 3 control water bottles in empty cages) and bottle weight and then 
dividing the amount of water consumption by number of days, and number of animals per 
cage.  Melatonin dosing was determined based on previous studies showing boosts in 
neurogenic potential, antioxidant effects, and white matter protection following pre-
treatment with 8mg/kg melatonin (Ramirez-Rodriguze et al., 2011) or 10mg/kg (Manda 
et al., 2009).  The chosen fluoxetine dose reflects a range of doses from 10mg/kg to 
20mg/kg used in studies that have found neurogenesis benefits following administration 
of fluoxetine in drinking water (Lyons et al., 2011; Lesemann et al., 2012) or delivered 
orally (Czeh et al., 2007).  Target doses of 12mg/kg melatonin (MP Biomedicals) and 
15mg/kg fluoxetine (Sigma-Aldrich) were diluted into drinking water with access to 
drinking water starting 21 days before chemotherapy treatment.  This timeline was 
chosen primarily to match the water administration time-line used by ELBeltagy et al. 
(2012).  For a visual indication of water pre-treatment relative to chemotherapy treatment 
see Figure 6. 
Chemotherapy and Neuroprotection Treatment:  Mice in each group received 
intraperitoneal (i.p.) injections over a period of 5 days (time-line shown in Figure 6).  5-
FU (70mg/kg diluted into 0.9% saline; Sigma-Aldrich) or saline (0.9% NaCl) injections 
were administered on days 1, 3, and 5, for a total of 3 injections per animal, as detailed in 
Han et al. (2008).  Dosing of 5-FU was based on maximally tolerated doses for C57BL/6J 
mice determined by previously piloted dosing studies done within our lab.  Han et al. 
(2008) used the same approach to determine the maximally tolerated dose of 5-FU in 
CBA mice.  Because toxicity and tolerance to chemotherapeutic compounds can vary 
 82 
drastically as a function of circadian rhythm (Focan, 1995), all mice were treated at 
approximately the same time, 8-9 hours after light onset. 
Animals treated with chemotherapy have a tendency to temporarily decrease their 
water intake following treatment, making it difficult to ensure neuroprotectant levels are 
maintained throughout treatment when administered via drinking water.  As a result, 
injections of neuroprotectants were administered to ensure that levels of protectants were 
maintained and maximally effective at the time of chemotherapy administration.  
Neuroprotection injections of melatonin (25mg/kg diluted in 0.9% saline; MP 
Biomedicals), fluoxetine (12mg/kg diluted into 0.9% saline; Sigma-Aldrich), or saline 
(0.9% NaCl) were delivered 20 minutes prior to chemotherapy and once every 24 hours 
for a total of 5 injections per animal.  As a result, mice received chemotherapy and 
neuroprotectant on days 1, 3, and 5, and a single neuroprotectant injection on days 2 and 
4 (see Figure 6).  Weight was monitored daily for approximately 4 weeks, then every 
other day until 56 days post-treatment.  Following day 56, mice were weighed weekly.  In 
addition to weight, teeth were monitored regularly and trimmed when necessary in order 
to prevent overgrowth which can lead to weight loss. 
Tissue Collection:  The same tissue collection procedure used in Experiment 1 was used.  
Immunohistochemical Staining:  The same immunohistochemical staining procedure 
used in Experiment 1 was used. 
Tissue Analysis:  The same tissue stain analysis protocol used in Experiment 1 was used. 
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Results Experiment 2 
Animal Deaths   
The only 5-FU induced animal deaths in Experiment 2 occurred within the day 56 
group.  No animal deaths occurred within the day 1 or 6 month groups in Experiment 2.  
Within the day 56 group, 1 animal injected with 5-FU, 2 animals injected with 5-FU + 
melatonin, and 2 animals injected with 5-FU + fluoxetine died prior to perfusion.  Any 
data collected for animals that died prior to perfusion were excluded from all analyses, 
including weight loss analyses (See Appendix E for mortality data regarding Experiment 
2). 
Neurogenesis Analysis Experiment 2 
Figure 7 shows the average number of Ki-67 positive cells detected in tissue for 
Experiment 2 across all three tissue collection time points (day 1, day 56, and 6 months).  
As shown in Figure 7, younger animals perfused at day 1 or day 56 had higher rates of 
cellular proliferation compared to older animals perfused at 6 months regardless of 
treatment condition.  Furthermore, pre-treatment with melatonin or fluoxetine did not 
alter the detected levels of neurogenic proliferation at any time point within the study.  A 
4 x 3 factorial ANOVA [Treatment × Day] indicated that there was a significant main 
effect of day, (F2, 66 = 17.65; p < .0001, ηp
2
 = .35), with no other significant effects 
detected.  Post hoc analysis (Tukey HSD) indicated that animals perfused at day 1 had 
significantly more Ki-67 positive cells than animals perfused at 6 months (p <.0001) and 
a trend for animals perfused at day 56 (p < .07).  Cell counts obtained from animals 
perfused at day 56 were significantly higher than those seen in animals perfused at 6 
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months (p < .005).  Together these results suggest a similar pattern to that obtained in 
Experiment 1.  While, 5-FU injections did not lead to any detectable differences in 
proliferation rates within the DG compared to saline injected animals, there was a 
decrease in proliferation over time as the animals aged.  Additional exploratory one-way 
ANOVA‘s confirmed there were no statically significant differences in the number of Ki-
67 positive cells across treatment conditions at any of these time points. 
Figure 7:  Experiment 2: Tissue Analysis 
 
 
 
Figure 7:  Mean number of Ki-67 positive cells detected in tissue collections at day 1, day 
56 and 6 month, for animals treated with saline, 5-FU, 5-FU + melatonin, and 5-FU + 
fluoxetine.  Error bars represent ±1 standard error of the mean.  A factorial ANOVA 
indicated a main effect of day, (p < .0001), with post-hoc analysis (Tukey HSD) 
indicating animals perfused at 6 months had significantly less Ki-67 positive cells than 
those animals perfused at day 1 (p < .0001) and at day 56 (p < .005).  No significant 
treatment effect was detected.   
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Weight Data Experiment 2 
Weight Loss Analysis:  Weight data was analyzed following the same procedures used in 
Experiment 1.  
Weights Day 1:  Figure 8 depicts percent weight (relative to pre-treatment weight) as a 
function of day, starting from the day of the first injection to the day after the last 
injection, for the animals that were perfused on day 1.  As shown in Figure 8, animals 
treated with 5-FU, regardless of protectant, all lost weight during the 5 day injection 
protocol, while control animals receiving saline maintained or gained weight.  A two-
factor mixed-design ANOVA [Treatment × Day] was conducted to analyze weight 
change between the treatment groups for the first 5 days of the experiment (starting from 
the day following the first injection to the first day following the last injection).  Results 
indicated main effects of treatment, (F3, 24 = 4.16; p < .017 ηp
2
 = .33), and day, (F4, 96 = 
17.53; p < .0001, ηp
2
 = .35), as well as a significant treatment by day interaction, (F12, 96 = 
12.53; p < .0001, ηp
2
 = .58).  This result follows the same pattern as Experiment 1, as 
weight for controls injected with saline increased during the injection protocol (the first 5 
days of the experiment) while 5-FU injected animals lost weight.  A one-way ANOVA 
confirmed that weight change differed by the end of the injection protocol (F3, 24 = 11.24; 
p < .0001, ηp
2
 = .58).  Post hoc analysis (Tukey HSD) indicated that the saline treated 
group had lost less weight than 5-FU only, 5-FU + melatonin, and 5-FU + fluoxetine 
treated groups (p’s < .002). 
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Figure 8:  Experiment 2: Weight Data - Day 1 
 
 
Figure 8: Mean % body weight (relative to pre-treatment weight) as a function of day for 
animals perfused on day 1.  Mice received IP injections of either saline (0.9% NaCl; n = 
7), 5-FU (70 mg/kg; n = 7), 5-FU + melatonin (25 mg/kg; n = 7), or 5-FU + fluoxetine 
(12 mg/kg; n = 7) on days 1-5 (protectants on all 5 days, 5-FU on days 1, 3, and 5). Error 
bars represent ±1 standard error of the mean. A two-factor mixed-design ANOVA 
indicated a main effect of treatment (p < .017), a main effect of day (p < .0001), and a 
treatment by day interaction (p < .0001). 
 
Weights Day 56:  Figure 9 depicts percent weight as a function of day, starting from the 
day of the first injection to the day after the last injection, for the animals that were 
perfused on day 56.  As shown in Figure 9, animals injected with 5-FU, regardless of 
protectant, all lost weight during the 5 day injection protocol, while control animals 
receiving saline maintained or gained weight. To assess differences in the extent of 
weight lost between the treatment groups across the protocol a two-factor mixed-design 
ANOVA [Treatment × Day] was conducted to analyze weight loss between the treatment 
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groups for the first 5 days of the experiment (starting from the day following the first 
injection to the first day following the last injection).  Results indicated main effects of 
treatment, (F3, 19 = 13.15; p < .0001, ηp
2
 = .68), and day, (F2.5, 46.8 = 90.81; p < .0001, ηp
2
 = 
.83, Greenhouse-Geisser corrected), as well as a significant treatment by day interaction, 
(F7.4, 46.8 = 10.20; p < .0001, ηp
2
 = .62, Greenhouse-Geisser corrected).  These results 
suggest that while weight increased over the first 5 days of the experiment for saline 
injected controls, 5-FU injected animals lost weight regardless of protectant.  A one-way 
ANOVA confirmed that weight change differed by the end of the injection protocol (F3, 19 
= 25.43; p < .0001, ηp
2
 = .80).  Post hoc analysis (Tukey HSD) indicated that the saline 
treated group had lost less weight than 5-FU only, 5-FU + melatonin, and 5-FU + 
fluoxetine treated groups (p’s < .002).  Additionally, there was a trend suggesting that the 
5-FU + melatonin group had lost less weight than the 5-FU only group (p = .071). 
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Figure 9:  Experiment 2: Weight Data - Day 56 
 
 
 
Figure 9: Mean % body weight (relative to pre-treatment weight) as a function of day for 
animals perfused on day 56.  Mice received IP injections of either saline (0.9% NaCl; n = 
7), 5-FU (70 mg/kg; n = 6), 5-FU + melatonin (25 mg/kg; n = 5), or 5-FU + fluoxetine 
(12 mg/kg; n = 5) on days 1-5 (protectants on all 5 days, 5-FU on days 1, 3, and 5). Error 
bars represent ±1 standard error of the mean. A two-factor mixed-design ANOVA 
indicated a main effect of treatment, a main effect of day and a treatment by day 
interaction (all p’s < .0001). 
 
 Another interesting feature of the weight data for Experiment 2 is the pattern of 
weight loss seen over the first month of the experiment.  Consistent with patterns of 
weight lost detected in previous experiments (Fremouw, et al., 2012a) and pilot testing, 
animals injected with 5-FU appear to go through two bouts of weight loss.  One of these 
occurs earlier, lasting through the 5 day injection protocol, while the second occurs 
following a transient period of weight gain and recovery (see Appendix F for a figure of 
the extended weight loss data). 
 89 
Weights 6 Month:  Figure 10 depicts percent weight as a function of day, starting from 
the day of the first injection to the day after the last injection, for the animals that were 
perfused at 6 months.  As shown in Figure 10, a similar consistent pattern of weight lost 
was observed in the 6 month animals when compared to those animals perfused on day 
56.  Again, animals injected with 5-FU, regardless of protectant, all lost weight during the 
5 day injection protocol, while control animals receiving saline maintained or gained 
weight.  A two-factor mixed-design ANOVA [Treatment × Day] was conducted to 
analyze weight loss between the treatment groups for the first 5 days of the experiment 
(starting from the day following the first injection to the first day following the last 
injection).  Results indicated main effects of treatment, (F3, 23 = 25.78; p < .0001, ηp
2
 = 
.77), and day, (F1.7, 39.8 = 53.93; p < .0001, ηp
2
 = .70, Greenhouse-Geisser corrected), as 
well as a significant treatment by day interaction, (F5.2, 39.8 = 7.50; p < .0001, ηp
2
 = .49, 
Greenhouse-Geisser corrected).  Consistent with the weight data obtained for the day 1 
and 56 animals, these results suggest that animals injected with saline alone maintained 
or increased their weight over the first 5 days of the experiment while 5-FU injected 
animals lost weight regardless of protectant.  A one-way ANOVA confirmed that weight 
change differed by the end of the injection protocol (F3, 23 = 24.76; p < .0001, ηp
2
 = .76).  
Post hoc analysis (Tukey HSD) indicated that the saline treated group had lost less weight 
than 5-FU only, 5-FU + melatonin, and 5-FU + fluoxetine treated groups (p’s < .001). 
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Figure 10:  Experiment 2: Weight Data - 6 months 
 
 
 
Figure 10: Mean % body weight (relative to pre-treatment weight) as a function of day 
for animals perfused on day 56.  Mice received IP injections of either saline (0.9% NaCl; 
n = 7), 5-FU (70 mg/kg; n = 7), 5-FU + melatonin (25 mg/kg; n = 6), or 5-FU + 
fluoxetine (12 mg/kg; n = 7) on days 1-5 (protectants on all 5 days, 5-FU on days 1, 3, 
and 5). Error bars represent ±1 standard error of the mean. A two-factor mixed-design 
ANOVA indicated a main effect of treatment, a main effect of day and a treatment by day 
interaction (all p’s < .0001). 
 
 Animals perfused at 6 months demonstrated the same pattern of two bouts of 
weight loss as detected in the animals perfused at day 56 (see Appendix G for a figure of 
the extended weight loss data). 
Discussion Experiment 2 
Treatment with 5-FU has been shown to reduce levels of proliferating cells within 
the DG of mice both shortly following treatment (Janelsins et al., 2010; 2 days after the 
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last chemotherapy injection) and up to 6 months after treatment completion (Han et al., 
2008).  In contrast, the results of the present study found no significant effect of 5-FU on 
proliferating cells within the DG at any of the assessment time points, including tissue 
collected at 1 day.  As with Experiment 1, the results from Experiment 2 conflict with 
these earlier reported reductions of neurogenesis following chemotherapy treatment in 
mice. 
It is unclear what the cause of theses discrepancies are.  It may suggest that 
reductions in proliferation rates within the DG shortly following treatment with 5-FU in 
rodents may not be as consistent or robust to experimental parameters as previously 
thought.  For instance, while many of the experimental parameters used in the present 
study were similar to those used by Han et al. 2008 (e.g. injection schedule, assessment 
windows) it appears that differences in a variety of factors including mouse strain and 
dose may have contributed to the different findings despite the similarities across the 
studies.  Considering that Han et al. (2008) had only been able to detect a statistically 
significant reduction in proliferation within the SVZ at 56 days after treatment while 
failing to detect a significant reduction in DG at this time point, the present study‘s lack 
of treatment effect at 56 days can be considered consistent with previous data.  This may 
suggest that populations of proliferative neurons within the DG may be less vulnerable to 
5-FU insult when compared to populations of neurogenic cells within the SVZ of rodents.  
When comparing the present study to the Janelsins et al. (2010) in which the same mouse 
strain and similar dose of 5-FU was administered, the present study failed to reproduce 
the early deficits in proliferation which had previously been reported.   
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When comparing results across the present study, Han et al. (2008), and Dietrich 
et al. (2006) the data appear to support not only the theory that each chemotherapeutic 
compound may exhibit a unique timing profile of neurogenic suppression but particular 
populations of these cells may be more vulnerable.  Taken together the complete lack of 
any 5-FU related long-term reduction in proliferation was unanticipated but highlights the 
fact neurogenesis assays may be susceptible to the same kinds of inconsistency present 
within the animal behavioral literature regarding CRCI.  
Again the recent study conducted by Seigers et al. (2016), provides experimental 
evidence that supports the present study‘s findings.  As Seigers et al. (2016) was unable 
to detect any reductions in proliferation within the DG of C57Bl/J6 mice treated with a 
single injection of 5-FU (75 mg/kg), when assessed utilizing Ki-67 for neurogenic 
proliferation at either 3 weeks or 16 weeks following treatment.  At both time points, 5-
FU treatment failed to produce any detectable differences in proliferation rates compared 
to saline treated controls.   
Finally it is difficult to evaluate the effectiveness of pre-treatment with melatonin 
or fluoxetine given that 5-FU did not cause a decrease in proliferation.  While previous 
studies in rats have indicated chronic fluoxetine treatment can boost proliferation rates 
within the DG (Duman et al., 2001), and co-administration of fluoxetine can prevent 
deficits in proliferation detected at less than one week following treatment with 5-FU 
(ELbeltagy et al., 2010) or methotrexate (Lyons et al., 2011), it is less clear if fluoxetine 
can boost levels of proliferation in otherwise healthy mice.  In a recent review, Miller and 
Hen (2015) report inconsistencies within the rodent literature regarding the capacity of 
fluoxetine to boost levels of adult hippocampal neurogenesis within healthy control mice.  
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They suggest that the most consistently detected increases in neurogenic proliferation 
following fluoxetine treatment occur in rodents that are stressed and/or animals 
displaying depression or anxiety-like behaviors.  This may suggest that fluoxetine would 
not be able to boost levels of proliferation within the DG of mice without an initial insult.  
Thus, it may be that fluoxetine was unable to induce any detectable differences in 
proliferation rates within collected tissue as 5-FU failed to disrupt normal rates of 
neurogenic proliferation.  The same may be true when considering the role of melatonin.  
While it was initially suspected that melatonin may have been a more powerful protectant 
against 5-FU related deficits, given both its neurogenic boosting and antioxidative effects 
in mice (Ramirez-Rodriguze et al., 2011) this was not supported given the lack of any 
treatment effects within Experiment 2.  
In summary, Experiment 2 found no treatment effects of 5-FU or any clear effects 
of pre-treatment with fluoxetine or melatonin on proliferation rates at any of the three 
time points within the study.  While unexpected, the lack of any significant differences 
detected between groups, as with Experiment 1, suggest that both short and long-term 
reported neurogenesis deficits may differ across studies and may be the result of 
variability across experimental parameters used.  
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GENERAL DISCUSSION 
Chemotherapy Toxicity   
 Given the lack of any treatment effects detected in either experiment, especially in 
tissue collected at day 1, the first potential explanation would be that chemotherapy 
dosing in the present study was insufficient to induce the deficits detected in previous 
studies.  While possible, this is highly unlikely given the decreases in weight seen in 
animals treated with chemotherapy.  The detected weight loss across both experiments 
indicates that the dosage used for each compound achieved the typical level of toxicity 
seen within the literature.  Furthermore, the dosing in the current study was equal to or 
higher than doses used in previous studies in which deficits have been detected at time 
points shortly after chemotherapy administration.  Given that in Experiment 1 and 2 a 
few animals died after receiving their chemotherapy, it seems likely that our 
chemotherapy doses where close to or slightly higher than the maximum tolerated dose. 
 Animal deaths that occurred across both experiments were minimal in most cases 
and unlikely to mask any treatment effects.  In particular, no animals died in any groups 
at 1 day and still no differences in neuronal proliferation were detected.  However, there 
was a portion of animals treated with doxorubicin in Experiment 1 that were lost prior to 
perfusions on day 56 and at 6 months.  As a result, it is difficult to interpret any potential 
treatment effects of doxorubicin within these groups without running additional animals. 
Age-Related Effects   
 It is clear from both experiments that proliferation rates decreased as the animals 
aged.  Tissue collected 1 day following completion of chemotherapy administration 
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exhibited the highest rates of Ki-67 positive cells regardless of the treatment condition.  
At later time points, rates of neurogenesis decreased, with the lowest detected rates of Ki-
67 positive cells observed in tissue collected at the 6 month time point.  This pattern of 
decreasing neurogenesis with increasing animal age was consistent across both 
experiments.  Furthermore, recent data collected by Seigers et al. (2016) demonstrated a 
similar reduction in proliferation within the DG of C57BL/6J mice between 3 weeks and 
16 weeks regardless of treatment with any of the chemotherapeutic compounds 
(cyclophosphamide , doxorubicin, or 5-FU) used in the present study.  
 The most likely explanation for these detected decreases in neurogenesis is 
natural aging.  While limited, studies show that adult mammalian hippocampal 
neurogenesis naturally undergoes significant decreases in rats (Kuhn, Dickinson-Anson, 
and Gage, 1996; Cameron and McKay, 1999; Bizon and Gallagher, 2003) and in mice 
(Kempermann et al., 1998; Harrist et al., 2004, Kronenberg et al., 2006).  A few studies 
have attempted to map out the time course of these age-related declines in neurogenesis 
(Seki and Arai, 1995; Rao, Hattiangady, and Shetty, 2006).  In one such study, Nada and 
Colleagues (2010) examined the time course of natural reductions of neurogenesis in 
C57BL/6J mice at 1-5, 7 and 9 months of age.  Utilizing Ki-67, Nada et al. (2010) 
observed an exponential decrease in proliferating cells within the subgranular zone of the 
dentate gyrus with increasing age.  An approximate 40% relative decrease in the number 
of proliferating cells was detected at each interval in the study.  The bulk of these 
decreases in neurogenesis occur within the first 6 months at which point they begin to 
plateau and then stabilize several months after.  
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 It seems likely that the progressive decrease in Ki-67 positive cells seen in the 
present study as the mice aged is the product of the natural age-related declines in 
neurogenesis.  Interestingly none of the treatment conditions seemed to significantly alter 
this natural age-related decline in either direction.  Importantly, the decrease in 
neurogenesis with age seen in the present study provides evidence that the Ki-67 
immunohistochemistry protocol was successful in labeling proliferating cells within the 
DG.  Thus the lack of any group differences in neuronal proliferation is unlikely to be 
caused by Ki-67 staining issues. 
Strain Differences   
 There are numerous, relatively well established phenotypic differences present 
between commonly used inbred strains of mice.  A limited number of these studies have 
identified variation in the rates of neurogenesis between the 9 most commonly used 
mouse strains, including C57BL/6J‘s (Kempermann, Kuhn and Gage 1997; Kempermann 
and Gage, 2002; Hayes and Nowakowski, 2002; Kim et al., 2009; Snyder et al., 2009).  
Understanding these differences may be critical when comparing rates of neurogenesis 
detected across multiple CRCI studies that have used these different strains of mice.   
 In the present study C57BL/6J mice were used.  Several studies have 
demonstrated that C57BL/6J mice have an unusually high rate of adult neurogenic 
proliferation within the hippocampus compared to other commonly used laboratory 
inbred strains (Kempermann, Kuhn and Gage 1997; Hayes and Nowakowski, 2002; Kim 
et al., 2009; Snyder et al., 2009).  It appears this increase in proliferation is coupled with 
a decrease in cell survival such that when those newly born cells are assessed 4 weeks 
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after birth, the number of these cells that survive in the C57BL/6J generally do not differ 
from those strains which previously had fewer cells present during proliferation 
(Kempermann, Kuhn and Gage, 1997; Hayes and Nowakowski, 2002).    It is unclear, if 
and how a higher basal rate of proliferation may affect detected rates of proliferation 
following chemotherapy administration.  Additionally, apoptotic assays used to assess 
DNA damage and cell death within the DG of C57BL/6J mice may be higher as a result 
of the strains inherent neurogenic process.  These strain based differences highlight the 
way in which different cellular assays of chemotherapy related effects may be susceptible 
to metabolic and cellular properties of a particular animal strain.  Whether researching the 
death of new cells or rates of cellular proliferation within the DG, attempts to 
characterize the effects of chemotherapy on neurogenesis may be unique to each 
chemotherapy compound and to each animal strain. Studies that compare effects across 
multiple inbred and outbred/wild strains may clarify these effects.  
 Taken together, these studies provide evidence that genetic variation between 
different inbred mouse strains can influence detected rates of neurogenesis.  It should be 
noted that the neurogenic assay used in this study, a Ki-67 marker, can only be used to 
assess proliferation rates.  Essentially, Ki-67 provides a snapshot of active proliferation at 
the time of tissue collection.  Given that C57BL/6J mice have especially high rates of 
neurogenic proliferation relative to other strains, it is possible that this fact may have 
acted to protect against chemotherapy induced insult or at the very least may have made 
it more difficult to detect any difference at the longer time points.  Conversely, it can be 
argued that by using C57BL/6J mice, the present study ensures the baseline level of 
neurogenic proliferation is high enough to detect any possible reductions due to 
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chemotherapy administration, thereby avoiding possible floor effects.  Although it is 
possible that strain related factors may account for differences in experimental results 
between Han et al.(2008), Dietrich et al. (2006) and the present study at the longer time 
intervals, it seems unlikely to account for the differences between these studies at shorter 
intervals given that Janelsins et al. (2010) have shown that C57BL/6J mice show similar 
decreases in neurogenesis shortly after chemotherapy injections.  Unfortunately, to date, I 
am not aware of any studies that directly compare rates of neurogenesis in C57BL/6J and 
CBA mice (which were used by both Han et al., 2008; and Dietrich et al., 2006) making 
it difficult explore strain related factors across studies.  Regardless of the factors that 
using the C57BL/6J strain may have introduced in the present study, the results are 
consistent with data collected in recent study conducted by Siegers et al.(2016) in which 
the same strain was assessed for chemotherapy related decreases in neurogenesis using 
Ki-67, in which no effects were detected at either 3 or 15 weeks post-treatment.    
Proliferation vs. Cell Survival   
 Marking for Ki-67 provides for a reliable assay of cellular proliferation.  However 
Ki-67 is unable to provide any information regarding rates of cell death, cell survival, 
cellular differentiation, or the status of successful integration of these new cells into 
existing neural networks.  It is possible that chemotherapy administration could spare 
proliferative processes while interfering with other processes involved in neurogenesis.  It 
should be noted that while proliferation, migration, differentiation, integration and 
maturation are all known to be important for successful neurogenesis, the exact timing 
and the mechanisms behind each of these processes are not thoroughly understood and 
are still actively being researched (Deng et al., 2010).     
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 The animal literature concerning CRCI has focused on neurogenesis as a potential 
underlying mechanism, but hasn‘t systematically differentiated the possible affects of 
chemotherapeutic compounds on neurogenic proliferation within the DG versus affects 
on the survival of these new neurons.  Only 2 studies have attempted to assess the affect 
of chemotherapy on cell survival within the DG and both have indicated that 
chemotherapy treatment can disrupt neurogenic cell survival (Mondie et al., 2010; Lyons 
et al., 2011).  While it is plausible that those cells actively proliferating would be the 
most vulnerable to the cytotoxic effects of chemotherapy exposure, it is unclear if a 
reduction in proliferation was detected, whether the loss of these proliferating cells 
during a brief injection protocol may represent significant damage or loss of function.  It 
may be that any brief reduction in proliferation may be compensated for through 
subsequent cellular proliferation events such that the net level of new granule cells within 
the DG is unaffected by chemotherapy treatment.  The ability of new granule cells to 
successfully survive and mature may be a critical factor rather than determining the 
number of proliferating cells at any one moment.     
 Assessing other factors in addition to proliferation, like those pertaining to cell 
survival and successful integration and maturation of granule cells into the hippocampus 
will be important for interpreting the contribution of chemotherapy induced neurogenesis 
deficits to CRCI.  Certainly the studies discussed above suggest that neurogenesis is a 
dynamic multifactor phenomenon whose processes may differ in terms of both baseline 
function and resiliency to insult as a function of genetic variation and age. 
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Future Directions 
The present study did not detect any reduction in proliferation rates within the DG 
of C57BL/6J mice treated with cyclophosphamide, doxorubicin, or 5-FU at 1 day, 56 
days or 6 months after treatment.  Additional animals may have been needed to overcome 
to the high variability of Ki-67 positive cells detected in tissue collected at day 1 in both 
experiments, to completely rule out any potential effects masked by this variability.  
However, it is fairly clear that there were no major alterations in proliferation rates within 
the DG in treated C57BL/6J mice at 56 days or 6 months compared to controls in both 
experiments.  This pattern of results suggests that neurogenesis processes involved with 
proliferation of cells within the DG are unaffected in C57BL/6J mice treated with these 
chemotherapeutic compounds.   
Within the human literature regarding CRCI it is well established that 
chemotherapy treatment seems to affect only a subset of individuals that undergo 
treatment for cancer.  Not unlike the human CRCI phenomenon, it is possible that the 
C57BL/6J inbred mouse strain used in the present study may be resistant to some of the 
neurobiological effects of chemotherapy treatment that lead to reduced neurogenesis rates 
detected in other mouse strains.  The lack of any alterations in neurogenesis rates in the 
current study are consistent with previous behavioral testing done in my lab that indicate 
no deficits in learning or memory following treatment with the same chemotherapy 
compounds (Fremouw et al., 2012a).  To confirm potential strain effects follow-up 
studies should utilize a variety of mouse strains, including wild type, to systematically 
assess the role genetic factors, relating to particular inbred strains, may have on 
chemotherapy related reductions in neurogenesis.  Furthermore, study of these strain 
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related factors may be able to identify particular genetic traits that may be protective and 
represent new treatment vectors. 
As previously discussed, proliferation of new cells within the DG represents only 
a small part of the complicated processes that underlie neurogenesis.  As a result, it will 
be necessary to use additional methodological tools to evaluate neurogenesis across each 
of these processes.  Future studies, will utilize additional cellar markers to such as DCX, 
to assess levels of immature neurons, NeuN, to mark fully mature neurons and BrdU, to 
assess survival of newly generated neurons throughout neurogenesis.  In addition, 
detection of cell death and DNA related apoptotic damage within the DG due to 
chemotherapy exposure should be assessed via terminal deoxynucleotidyl transferase 
(TdT) dUTP nick-end labeling (TUNEL) assays.  These assays and immnohistochemical 
markers can be used in conjunction with more sophisticated imaging software to assess 
morphological features such at dendritic complexity and length, within these neurons, 
and critically throughout the neurogenesis process.   
Other neurobiological targets and potential mechanism that may relate to CRCI 
still need to be explored.  Additional experiments done in my lab have already identified 
deficits in white matter following treatment with 5-FU or a combination treatment of 
cyclophosphamide and doxorubicin 14 months after treatment.  Interestingly, preliminary 
data generated from the same animals show an increased expression of ionized calcium-
binding adapter molecule 1 (iba1), indicative of upregulation of microglia activity and 
neuroinflammation within the CNS.  These convergent results suggest that chemotherapy 
treatment in C57BL/6J mice may eventually induce long-term neuroinflammatory states 
and deficits in white matter integrity within the CNS. 
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The present study and others are needed to help identify and clarify the 
underlying mechanisms responsible for CRCI.  Long-term experiments that examine 
neurogenesis and other cellular processes within the CNS that may be vulnerable to 
chemotherapeutic agents are needed within the CRCI literature.  The goal of these 
experiments should be to systematically establish unique profiles for each 
chemotherapeutic agent, that address the cellular targets and mechanisms involved as 
well as the timing of any detected effects.   These studies will facilitate research being 
done in patient populations that explore factors related to cognitive dysfunction following 
chemotherapy treatment and how to mitigate, prevent and repair damage done to patients 
who receive chemotherapy treatment. 
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APPENDIX A. REPRESENTATIVE BRIGHT-FIELD MICROGRAPHS 
 
Figure 11: Representative Bright-Field Micrographs 
 
 
 
 
 
 
 
Figure 11: Representative bright-field micrographs of control animals perfused at day 1 
(A), day 56 (B) and 6 Months (C)
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APPENDIX B. MORTALITY DATA EXPERIMENT 1 
 
Figure 12: Mortality Rates: Experiment 1 
 
 
 
 
Figure 12: Graphs of the % of animals surviving as a function of day for animals in 
experiment 1 from day 1 to day 35.  A indicates % survival of day 1 animals.  B indicates 
% survival of day 56 animals. C indicates % survival of 6 month animals. 
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APPENDIX C. EXPERIMENT 1: EXTENDED WEIGHT DATA - 56 DAYS 
 
Figure 13: Extended Weight Data Experiment 1 - Day 56 Animals 
 
 
 
Figure 13:  Mean % body weight (relative to pre-treatment weight) as a function of day 
for animals perfused at day 56 in experiment 1.  Mice received IP injections of either 
saline (0.9% NaCl; n = 7), cyclophosphamide (120 mg/kg; n = 7), or doxorubicin (5 
mg/kg; n = 4), on days 1, 4, and 7 (INJ1, INJ2 and INJ3). Error bars represent ±1 
standard error of the mean. 
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APPENDIX D. EXPERIMENT 1: EXTENDED WEIGHT DATA - 6 MONTHS 
 
Figure 14: Extended Weight Data Experiment 1 - 6 Month Animals 
 
 
 
Figure 14:  Mean % body weight (relative to pre-treatment weight) as a function of day 
for animals perfused at 6 months in experiment 1.  Mice received IP injections of either 
saline (0.9% NaCl; n = 7), cyclophosphamide (120 mg/kg; n = 7), or doxorubicin (5 
mg/kg; n = 4), on days 1, 4, and 7 (INJ1, INJ2 and INJ3). Error bars represent ±1 
standard error of the mean 
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APPENDIX E. MORTALITY DATA EXPERIMENT 2 
Figure 15: Mortality Rates: Experiment 2 
 
 
 
 
Figure 15: Graphs of the % of animals surviving as a function of day for animals in 
experiment 2 from day 1 to day 35.  A indicates % survival of day 1 animals. B indicates 
% survival of day 56 animals. C indicates % survival of 6 month animal 
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APPENDIX F. EXPERIMENT 2: EXTENDED WEIGHT DATA - 56 DAYS 
 
Figure 16: Extended Weight Data Experiment 2 - Day 56 Animals 
 
 
 
Figure 16: Mean % body weight (relative to pre-treatment weight) as a function of day 
for animals perfused on day 56 in experiment 2.  Mice received IP injections of either 
saline (0.9% NaCl; n = 7), 5-FU (70 mg/kg; n = 6), 5-FU + melatonin (25 mg/kg; n = 5), 
or 5-FU + fluoxetine (12 mg/kg; n = 5) on days 1-5 (protectants on all 5 days, 5-FU on 
days 1, 3, and 5). Error bars represent ±1 standard error of the mean. 
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APPENDIX G. EXPERIMENT 2: EXTENDED WEIGHT DATA - 6 MONTHS 
 
Figure 17: Extended Weight Data Experiment 2 - 6 Month Animals 
 
 
Figure 17: Mean % body weight (relative to pre-treatment weight) as a function of day 
for animals perfused at 6 months in experiment 2.  Mice received IP injections of either 
saline (0.9% NaCl; n = 7), 5-FU (70 mg/kg; n = 7), 5-FU + melatonin (25 mg/kg; n = 6), 
or 5-FU + fluoxetine (12 mg/kg; n = 7) on days 1-5 (protectants on all 5 days, 5-FU on 
days 1, 3, and 5). Error bars represent ±1 standard error of the mean. 
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